Document:

Materials Intellectual Property Agreement, dated November 13, 2001

 Exhibit 10.18.1 
  

	(1)	Cambridge Display Technology Limited 

  

	(2)	The DOW Chemical Company 

  
 Materials Intellectual Property Agreement 
  
 Dated: 13th November 2001 
  
 CONFIDENTIAL TREATMENT REQUESTED: INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED FROM THIS DOCUMENT. SUCH
OMISSIONS ARE NOTED BY “[**]”. AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN SUBMITTED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION. 

 Contents 
  

					
	 1.
	  	Definitions and interpretation	  	1
			
	 2.
	  	Grant of licence, Patent procurement, and Patent enforcement	  	4
			
	 3.
	  	Assignment	  	7
			
	 4.
	  	Financial Provisions	  	7
			
	 5.
	  	Joint Marketing Activities	  	9
			
	 6.
	  	Materials	  	9
			
	 7.
	  	Accounts	  	10
			
	 8.
	  	Duration and Termination	  	10
			
	 9.
	  	Effects of Termination	  	11
			
	 10.
	  	Confidentiality	  	11
			
	 11.
	  	Force majeure	  	12
			
	 12.
	  	Nature of Agreement	  	13
			
	 13.
	  	Governing Law and Jurisdiction	  	14
			
	 14.
	  	Notices	  	14
			
	 15.
	  	Further assurance	  	15
			
	 16.
	  	Waiver	  	15
			
	 17.
	  	Exclusion of warranties	  	15
			
	 18.
	  	Severance	  	16
			
	 19.
	  	Announcements	  	16
			
	 20.
	  	Non-Solicitation	  	16

  
  

 i 

 This Agreement is made the 13th day November, 2001 
  
 Between: 
  

	(1)	Cambridge Display Technology Limited (company number 2672530) whose registered office is at Greenwich House, Madingley Rise, Madingley Road, Cambridge CB3 0H7
(“CAT”); and 

  

	(2)	The Dow Chemical Company whose primary place of business is at 2030 Building, Midland, MI 48674 (“DOW”). 

  
 Background: 
  

	(A)	CDT has the right to grant licenses under certain patents and Know-how relating to polyfluorene-based materials. 

  

	(B)	CDT is prepared to grant licenses under such patents and Know-how on reasonable terms and conditions to financially sound and commercially responsible applicants.

  

	(C)	DOW is desirous of acquiring and CDT is willing to grant, subject to certain terms and conditions, a Licence to make, use or sell products utilising the claims of such patents or
such Know-how. 

  
 It is agreed as follows: 
  

	1.	Definitions and interpretation 

  

	 	1.1	In this Agreement unless the context otherwise requires: 

  

			
	“Licensed Patents”	 	shall mean the patent publications set forth in Appendix A as may be modified in the future by written requests from DOW to add or delete patent publications from the list. Appendix A shall
be updated at least annually to reflect patent applications that have been abandoned as well as continuation, divisional or national stage applications that may have been filed.
		
	“Patents”	 	means all patents owned or controlled by CDT, including patents of importation, improvement patents, patents and certificates of addition, and utility models, as well as divisions, reissues,
continuations, renewals, and extensions of any of the foregoing, and applications therefor (including patents which may issue on such

  

 3 

			
	 	 	applications) covering inventions with respect to which the first application for a patent was filed prior to the date of termination of this Agreement.
		
	“Know-how”	 	means all confidential and proprietary information including trade secrets, skills, experience, knowledge, techniques, processes, procedures, designs, technical data and information
developed, accumulated or conceived by CDT prior to and during the term of this Agreement relating to the licensed products or the Licensed Patents, and all designs, drawings, reports, memoranda, blueprints, specifications and the like, prepared by
CDT, which relate to the development, design, manufacture, sale or use of products embodying the licensed patents.
		
	“this Agreement”	 	means this Agreement (including any schedule or annexure to it and any document in agreed form);
		
	“Affiliate”	 	shall mean any corporation, company or other entity (a) which owns mote than fifty percent (50%) of a Party hereto (referred to herein as “Parent”), (b) of which more than fifty
(50%) is owned by or controlled by a Party hereto or (c) of which more than fifty (50%) is owned by or controlled by a Parent of a Party hereto, but such corporation, company or other entity shall be deemed to be an Affiliate only as long as such
affiliation exists.
		
	“Net Sales”	 	means gross sales accepted and shipped by DOW or its Affiliates and accepted and paid for by customers, less all trade and cash discounts, the amount of returns and allowances (including
freight but not including advertising allowances); provided, however, that in the first instance, royalty payments shall be made on merchandise shipped and accepted by DOW’s customers during the preceding calendar quarter, subject to later
credit for anon payments.
		
	“LEP”	 	means light emitting polymer relating to large molecule organic electroluminescent material.
		
	“Licence”	 	means the licence granted pursuant to Section 2.6 and detailed in Schedule 2.

  

 4 

			
	“Polyfluorenes”	 	means any polymer having substituted or unsubstituted 2,7 linked fluorene mer units but does not include polymers where all the fluorene units are spirofluorenes or
indenofluorenes.
		
	“Polyfluoren-Based Material”	 	means (a) Polyfluorenes; (b) solid compositions containing Polyfluorenes in an amount of at least one percent (1%) by weight; and (c) solutions containing Polyfluorenes not including
formulations for ink jetting.
		
	“PF Ink Jet Formulations”	 	Means solutions containing Polyfluorenes for ink jet application.
		
	“a Quarter”	 	means any three month period commencing January 1, April 1, July 1, or October 1.
		
	“Year”	 	means the period of twelve month period commencing with the first full Quarter after the effective date of this Agreement and each subsequent consecutive period of twelve months during the
period of this Agreement and any shorter period ending on its termination.
		
	[**]	 	[**]
		
	[**]	 	[**]
		
	 “Photovoltaic and
 Photodetector
 device”
	 	semi-conducting devices containing conjugated polymers that absorb light in the conjugated polymer and convert it to current and/or voltage.

  

	 	1.2	Also in this Agreement, unless the context otherwise requires: 

  

	 	(a)	words in the singular include the plural and vice versa and words in one gender include any other gender; 

  

	 	(b)	a reference to Sections and schedules is to Sections of and schedules to this Agreement and references to subsections and paragraphs are references to sub-Sections and paragraphs of
the Section or schedule in which they appear; 

  

 5 

	 	(c)	the table of contents and headings ate for convenience only and shall not affect the interpretation of this Agreement. 

  

	2.	Grant of licence, Patent procurement, and Patent enforcement 

  

	 	2.1	CDT grants to DOW, and DOW accepts, the following licenses, subject to the provisions of this Agreement: 

  

	 	(a)	an exclusive license under Licensed Patents (and associated Know-how) to make, have made, use, sell and import PolyFluorene-Based Materials in any and all countries of the world.
This license includes process technology relating to the Suzuki Coupling reaction; 

  

	 	(b)	a non-exclusive license under Licensed Patents (patents and Know-how) for all process technology relating to the Suzuki coupling reaction for use in making materials other than
PolyFluorene-Based Materials in any and all countries of the world; 

  

	 	(c)	a non-exclusive license under CDT Patents (including GB 01/00852 and its equivalents) to make, have made, use, sell and import PF Ink Jet Formulations in any and all countries of
the world, provided that such Intellectual Property is wholly-owned and free to be licensed as of the date of this Agreement, or for later made inventions, as of the date of the invention; 

  

	 	(d)	a non-exclusive license under CDT Patents relating to Spiro and IndenoFluorones to make, have made, use, sell or import LEPs containing spiro and indenofluorenes in any and all
countries of the world, provided that those patents are wholly-owned and free to be sublicensed as of the date of this Agreement, or for later made inventions, as of the date of the invention; and 

  

	 	(e)	a royalty-free non-exclusive license under CDT’s intellectual property to make test devices for screening and developing new materials. 

  

	 	2.2	It is acknowledged that the transfer of all Know-how specified in this Section from CDT to DOW shall be considered to be completed twelve (12) months from the execution date of this
Agreement unless DOW notifies CDT at least thirty (30) days prior to the expiration of this twelve month period that it believes it has not received all of the Know-how. 

  

 6 

	 	2.3	Nothing in this Agreement shall be construed as granting to DOW any right under any patents, patent applications, trademarks, trademark applications or Know-how owned by CDT or its
Affiliates except as specifically set forth herein. 

  

	 	2.4	No right to grant sublicenses is granted under this Agreement. Notwithstanding the preceding, DOW may grant sublicenses to its Affiliates. 

  

	 	2.5	CDT further hereby grants to DOW an option to obtains a nonexclusive license under CDT patents issued or published as of June 1, 2001 to make, use, sell or otherwise dispose of
light emitting polymers other than Polyfluorenes at a mutually agreed-upon royalty rate for such sales. 

  

	 	2.6	CDT further grants to DOW an option to take a Licence under the terms set forth in the license agreement attached hereto as Schedule 2, to make, have made and sell light emitting
polymer devices under its patent portfolio including patent application number WO 90/13148. This option may be transferred to an entity in which DOW holds an initial equity position of at least [**] percent ([**]%), provided that: (i) the entity may
not manufacture components containing CDT intellectual property within the Peoples Republic of China; and (ii) in the case of entities which propose to manufacture in countries other than North America, Western Europe and Japan, prior written
approval from CDT must be obtained, such approval not to be unreasonably withheld. 

  
 DOW may convert this option to a Licence at any time within [**] of the date of this Agreement. If a Licence is signed within [**] of the date of this
Agreement then the principal terms of the agreement shall be no less advantageous than the terms of the agreement attached as Schedule 2. In the event a Licence is entered into after [**] but before the [**] anniversary of this Agreement, the
conditions of the Licence shall be no less advantageous than the standard license terms being offered by CDT at the time DOW informs CDT that it (or its IV entity) wishes to enter into negotiations with CDT to conclude a Licence, provided that such
negotiations are concluded within [**] of notice of negotiation being given. 
  

	 	2.7	CDT agrees not to manufacture or sell Polyfluorene-Based Materials during the term of this agreement. 

  

	 	2.8	For those Licensed Patents under which DOW has received a license under clause 2.1, CDT shall notify DOW of any change in the status of patents or patent applications. For those
Licensed Patents under which 

  

 7 

 DOW has received an exclusive license under clause 2.1(a), CDT shall promptly notify DOW in writing if
CDT elects not to continue prosecution of any patent application or to maintain any patent. DOW shall have the right to continue patent prosecution or to maintain any such patent at its own cost, such patent shall be assigned to DOW and DOW shall
retain no right or interest in that Patent. Furthermore, there shall be no royalty due to CDT for sales of any Polyfluorene-Based Material that are covered only by the assigned patent and are not covered by any other Licensed Patent. 
  

	 	2.9	In the event that any third party shall infringe any claims of Licensed Patents in the field under which DOW received an exclusive license in clause 2.1(a), DOW may, at its option,
send written notice thereof to CDT requesting that CDT take action to abate such infringement. 

  

	 	(a)	if CDT elects to pursue action to abate such infringement, CDT will use its best endeavours to abate such infringement. If such infringement is nevertheless not abated within 18
months of DOW providing notice to CDT, royalties due under section 4.1 shall be reduced by [**]% until such time as the infringement is abated. 

  

	 	(b)	If CDT elects not to abate such infringement and provide DOW notice of that decision or if CDT has failed to file and be diligently pursuing a lawsuit within three months of
receiving notice of such infringement, DOW shall have the right to undertake proceedings (in CDT’s name if necessary) against any third party for infringement of the particular claim in question under the relevant patent or patent application.
DOW shall retain all money damages recovered in such a lawsuit pursued by DOW. 

  

	 	2.10	CDT agrees to make available to DOW the results of its joint development programs in so far as those programs relate to Polyfluorenes, and their uses and to the extent permitted by
the joint development partner and the agreement with such partner. 

  

	 	2.11	CDT agrees not to sue DOW for contributory infringement under CDT owned patents on polymer light emitting devices to the extent the products supplied by DOW are being used by
DOW’s customers for Research and Development purposes and not to produce devices for commercial sale. CDT will notify DOW if it believes DOW is contributory infringing CDT patents by supply to a customer producing LEP displays for commercial
sale, will identify the relevant customer(s), and will not pursue any suit against DOW for the alleged contributory infringement unless DOW has not ceased sales to such customer(s) within [**] of receiving the notice from CDT.

  

 8 

	 	2.12	CDT agrees to withdraw its opposition to DOW’s European Patent No. 842208B1. 

  

	3.	Assignment 

  

	 	3.1	CDT shall assign, and at the request of DOW amend the inventors of, patent application number WO 00/55927 (and any national or regional patents, including continuations and
divisionals thereof) to DOW. Upon assignment of this application, DOW shall grant to CDT a non-exclusive, worldwide, royalty-free license to make, have made, develop, use, sell or otherwise transfer polymers (excluding Polyfluorene-Based Materials)
under this application. [**] 

  

	 	3.2	Upon assignment of the above mentioned patent family, DOW will reimburse CDT for the filings fees and translation costs associated with entering the national or regional stage in
the following countries: Canada, United States, EPO (designating all), China, Japan, Singapore, and South Korea. 

  

	 	3.3	CDT and DOW agree that the above license and assignment settles the dispute regarding alleged breach of confidentiality caused by the filing of the patent application WO 00/55927.

  

	4.	Financial Provisions 

  

	 	4.1	In consideration of the rights granted under this Agreement the DOW will pay to CDT or its designated Affiliate, a royalty on all sales of Polyfluorene-Based Materials for light
emission applications and for use in Photovoltaic and Photodetector devices. This royalty will be: a royalty 

  

 9 

 of [**] percent ([**]%) of DOW’s Net Sales [**]. The obligation to pay a royalty shall cease after
[**] or with the last to expire valid Licensed Patent having a claim which would be infringed by Polyfluorene Based Materials sold by DOW, which ever comes later. The Net Sales shall not include sales to CDT or its Affiliates. 
  

	 	4.2	The royalties payable pursuant to Section 4.1 shall be paid within sixty (60) days after each Quarter during the period of this Agreement. DOW shall submit to CDT a written report
showing: 

  

	 	(a)	Net Sales of all Polyfluorene-Based Material; and 

  

	 	(b)	the amount of the royalties payable pursuant to Section 4.1 in respect thereof. 

  

	 	4.3	All royalties or other sums payable under this Agreement shall be paid in US Dollars (US$), and where the underlying price in respect of which any royalty is so payable is stated in
a currency other than US$, it shall be converted into US$ by reference to the average of the relevant daily buying and selling rates of CitiBank, New York for the currency in question over the Quarter in question. 

  

	 	4.4	All sums payable pursuant to this Agreement are exclusive of value added tax or other applicable taxes or duties for which DOW shall be additionally liable and shall be paid in
cleared funds to such bank account as CDT may from time to time nominate, without any set off, deduction or withholding except such amount (if any) of tax as DOW is required to deduct or withhold by law. If DOW is required by law to make any tax
deduction or withholding, DOW shall do all things in its power which may be necessary to enable or assist CDT to claim exemption therefrom under any double taxation or similar agreement from time to time in force and shall from time to time give CDT
proper evidence as to the deduction or withholding and payment over of the tax deducted or withheld. 

  

	 	4.5	If DOW makes any default in payment of the royalties due hereunder the amount due shall bear interest, compounded monthly at the U.S.A. Prime Rate plus [**] percent [**], prorated
daily until payment of said unpaid royalty and interest is made in full. The U.S.A. Prime Rate shall be deemed to be that quoted in the “Money Rates” table of the Wall Street Journal published on the second business day of each month. If a
range of Prime Rates is quoted, the highest percentage shall apply. If no “Money Rates” table appears in the Wall Street Journal on the second 

  

 10 

 business day, the U.S.A. Prime Rate next appearing in the “Money Rates” table of said journal
shall be used. Payments should be made to [**]. 
  

	5.	Joint Marketing Activities 

  

	 	5.1	At DOW’s request, CDT agrees to provide DOW introductions to CDT’s licensees and to participate in one initial meeting between DOW and such licensee, to the extent such
CDT licensee is willing to meet with DOW. Such meetings will take place within four (4) months of the signing of this Agreement. CDT and DOW also intend to issue a joint press release announcing the signing of this Agreement and further discussing
the relationship within two (2) months of the signing of this Agreement. CDT also intends to provide advice to its licensees on how to use DOW materials in the most efficient manner possible to facilitate the commercialisation of polymer OLED
displays. 

  

	6.	Materials 

  

	 	6.1	DOW agrees to provide [**] up to [**] grams per year of Polyfluorene-based Materials for CDT’s use in internal research activities on making light emissive devices provided DOW
receives sixty (60) days notice of orders exceeding [**] grams, and less than [**] grams of the [**] grams is required to be made in the laboratory. For each additional gram of material above [**] grams (or [**] grams made in the laboratory) ordered
in the calendar year, DOW intends to charge [**] dollars (US $[**]) per gram. The parties intend to re-evaluate the price each new calendar year and adjust the price based on sampling prices to other customers for like grades of material for like
applications. 

  

	 	6.2	DOW agrees to provide up to [**] grams of material to CDT at a price of [**] dollars (US $[**]) per gram for each CDT research licence / technology introduction package. A research
license / technology introduction package is a signed agreement between CDT and a display device manufacturer whereby CDT supplies device manufacturing information and [**] ([**] grams) of material, all this is supplied for an overall fee with no
specific charge for the material being made. If DOW believes the material which DOW and CDT agree should be supplied is proprietary to DOW, the research license must include language regarding confidentiality, limited use, and non-analysis
consistent with DOW’s standard practice for such materials. The parties 

  

 11 

 intend to re-evaluate the price each new calendar year and adjust the price based on sampling prices to
other customers for like grades of material for like applications. 
  

	 	6.3	DOW further agrees to negotiate a supply agreement with CDT [**] (excluding terms to DOW’s Affiliates) to supply CDT with Polyfluorene-based Materials for CDT’s use in
light emitting device manufacture. Such Polyfluorene-Based Materials may not be used by CDT for resale, resampling or preparing ink jet formulations for sale. [**] Additionally, these terms will apply to a maximum of three (3) Affiliates or Joint
Ventures where CDT has at least a fifty percent (50%) ownership. 

  

	7.	Accounts 

  

	 	7.1	DOW shall keep for a period of three (3) years following the due date for the report specified in 4.2 records in sufficient detail to enable the amount of all royalties and other
sums due and payable under this Agreement to be determined. 

  

	 	7.2	Not more than once per calendar year, DOW shall at the reasonable request of CDT allow an independent royalty auditor to inspect those records and books of account at all reasonable
times during normal business hours and report to CDT on whether DOW has paid all the royalties due and, if not, the arrearage that DOW owes. 

  

	 	7.3	Inspections under Section 7.2 shall be carried out at CDT’s expense. However if the audit proves that DOW’s accounting of royalties was deficient by more than five percent
(5%) of the money actually due, the cost of such inspection shall be borne by DOW. 

  

	8.	Duration and Termination 

  

	 	8.1	Either patty may forthwith terminate this Agreement by written notice to the other if: 

  

	 	(a)	the other party has committed any breach of any of its obligations under this Agreement (other than Section 11) and (in the case of a breach which is capable of remedy) has failed
to remedy the same within the period of sixty (60) days after receipt of written notice giving full particulars of the breach and requiring it to be remedied; or 

  

 12 

	 	(b)	the other party goes into liquidation (except for the purposes of amalgamation or reconstruction and in such manner that the company resulting therefrom effectively agrees to be
bound by or assume the obligations imposed on that other party under this Agreement); 

  
 or any analogous event to the foregoing under the law of any jurisdiction occurs in relation to the other party. 
  

	 	8.2	For the purposes of Section 8.2(a), a breach shall be considered capable of remedy if the party in breach can comply with the provision in question in all respects other than as to
the time of performance (provided that time of performance is not of the essence). 

  

	 	8.3	For the avoidance of doubt the rights to terminate this Agreement given by this Section shall not prejudice any other right or remedy of either patty in respect of the breach
concerned (if any) or any other breach. 

  

	9.	Effects of Termination 

  

	 	9.1	On termination of this Agreement for any reason: 

  

	 	(a)	DOW shall cease to use, either directly or indirectly, the Patents (unless and to the extent expired); 

  

	 	(b)	DOW shall consent to the cancellation of any formal licence granted to it, or of any recordal of it in any register, in relation to any of the Patents; 

  

	 	(c)	subject as provided in this Section, told except in respect of any accrued rights, neither party shall be under any further obligation to the other; and 

  

	 	(d)	all obligations of either party under this Agreement which are expressed to or by implication are intended to survive its termination shall continue thereafter.

  

	10.	Confidentiality 

  

	 	10.1	DOW acknowledges that all Know-how accumulated by CDT is extremely valuable to CDT and that the disclosure of such Know-how by DOW to any unauthorised third party may cause CDT
irreparable harm. Accordingly, DOW may use Know-how obtained from CDT for the sole purpose of manufacturing and selling Polyfluorene-Based Materials under this Agreement. These permitted uses include, among other things, 

  

 13 

 disclosure of information inherent in the sale or other distribution of Polyfluorene-Based Materials,
disclosure of methods of manufacture of Polyfluorene-Based Materials in exercise of have made license, and, subject to an obligation of confidentiality, disclosure of methods use of the Polyfluorene-Based Materials in connection with a sale of such
materials. For a period of five (5) years from the date of disclosure, DOW shall not divulge the Know-how or any portion thereof to an unauthorised third party, not shall DOW use the Know-how or any portion thereof except as licensed, unless the
Know-how or portion thereof (i) was known to DOW prior to its receipt from CDT; (ii) became known to DOW from sources other than either directly or indirectly from CDT; (iii) became a matter of public knowledge; other than by breach of this
Agreement by DOW; (iv) which CDT has agreed to permit DOW to disclose to third parties; or (v) which was divulged as a result of a court order or other government action. Notwithstanding the foregoing, no disclosure shall be made pursuant to Section
10.1(v) without DOW first giving CDT reasonable notice prior to the intended disclosure of such Know-how so as to allow CDT an opportunity to object to such disclosure and obtain an appropriate protective order or other Safeguard, DOW shall have no
obligation of confidentiality or limited use with regard to information received from CDT unless it is marked as “CDT Confidential” or if first received in non-tangible form is indicated to be confidential at the time of disclosure and is
summarized in a writing delivered to DOW within 30 days of the initial disclosure. 
  

	 	10.2	Business and technical information relating to DOW’s polyfluorene and light emitting polymer business which is disclosed by DOW to CDT shall be treated in accordance with the
Confidentiality Agreement between the Parties having an effective date of June 20, 2001 and all extensions thereto (DOW Agreement 204684) 

  

	 	10.3	The terms of this Agreement are confidential and shall not be disclosed by either Party to a third party without prior written consent of the other Party to this Agreement.

  

	11.	Force majeure 

  

	 	11.1	Neither party shall be deemed to be in breach of this Agreement, or otherwise be liable to the other, by reason of any delay in performance or non-performance of any of its
obligations under this Agreement to the extent that such delay or non-performance is due to any cause beyond its reasonable control including but not limited to any strike, lockout or other form of industrial action (an “Event of Force
Majeure”). 

  

 14 

	 	11.2	The party affected by the Event of Force Majeure shall immediately give the other party written notification of the nature and extent of the Event of Force Majeure and the parties
shall enter into bona fide discussions with a view to alleviating its effects or to agreeing upon such alternative arrangements as may be fair and reasonable. 

  

	12.	Nature of Agreement 

  

	 	12.1	Either Party may transfer both the benefit and burden of this Agreement by way of a novation to any purchaser or other successor in title (whether by way of an initial public
offering, sale, reorganisation, amalgamation or otherwise) of all or substantially all of its business to which this agreement pertains. 

  

	 	12.2	Nothing in this Agreement shall create, or be deemed to create, a partnership, or the relationship of principal and agent, between the parties. 

  

	 	12.3	DOW warrants to CDT that: 

  

	 	(a)	it has the authority to enter into this Agreement; and 

  

	 	(b)	the execution of, and the performance of its obligations under, this Agreement require no governmental or other approvals or, if required, such approvals have been obtained.

  

	 	12.4	CDT warrants to DOW that: 

  

	 	(a)	it has the authority to enter into this Agreement; and 

  

	 	(b)	the execution of, and the performance of its obligations under, this Agreement require no governmental or other approvals or, if required, such approvals have been obtained; and

  

	 	(c)	it has the right to grant the licenses granted herein. 

  

	 	12.5	Neither Party shall be liable to the other for any indirect or consequential losses, damages, costs or expenses incurred by reason of any duty at common law or under any statute, or
any representation (other than fraudulent misrepresentation), or any term hereof, whether express or implied by statute, collaterally or otherwise, nor for any loss of profit, business, goodwill, anticipated savings or contracts, however the same
may arise and whether occasioned by the negligence, breach of contract or otherwise of the Party, its servants or agents or otherwise, which arises out of or in connection with this Agreement. 

  

 15 

	 	12.6	Each Party acknowledges that it has entered into this Agreement in reliance only upon the representations, warranties and promises specifically contained or incorporated in this
Agreement and, save as expressly set out in this Agreement, neither party shall have any liability in respect of any other representation, warranty or promise made prior to the date of this Agreement unless it was made fraudulently.

  

	13.	Governing Law and Jurisdiction 

  

	 	13.1	This Agreement shall be governed by and construed in accordance with English law. 

  

	 	13.2	Each of the parties irrevocably submits for all purposes in connection with this Agreement to the exclusive jurisdiction of the courts of England. 

  

	14.	Notices 

  

	 	14.1	Any notice to a party under this Agreement shall be in writing signed by or on behalf of the party giving it and shall, unless delivered to a party personally, be left at, or sent
by registered or certified mail to the address of the party as set out below: 

  

			
	 For DOW:

	
	 To: Rob Spurling, Director, Advanced Electronic Materials, Displays

	 	  	1702 Building
	 	  	The DOW Chemical Company
	 	  	Midland, MI 48674
	
	 With a copy to:

		
	 	  	Susan M. Zerull
	 	  	Intellectual Property Law Section
	 	  	1790 Building
	 	  	The DOW Chemical Company
	 	  	Midland, MI 48674
	
	 For CDT:

		
	 To:
	  	Richard Bennett
	 	  	CDT
	 	  	Greenwich House Madingley Rise
	 	  	Madingley Road, Cambridge CB30HJ

  

 16 

	 	14.2	Except as referred to in sub-Section 14.3, a notice shall be deemed to have been served: 

  

	 	(a)	at the time of delivery if delivered personally; 

  

	 	(b)	on the date noted on the receipt for registered or certified mail. 

  

	 	14.3	A party shall not attempt to prevent or delay the service on it of a notice connected with this Agreement. 

  

	15.	Further assurance 

  
 After this Agreement has been signed by both parties, each party shall execute such documents and take such steps as the other party may reasonably
require to fulfil the provisions of and to give to each party the full benefit of this Agreement. 
  

	16.	Waiver 

  

	 	16.1	The rights, powers and remedies conferred on any party by this Agreement and remedies available to any party are cumulative and are additional to any right, power or remedy which it
may have under general law, this Agreement or otherwise. 

  

	 	16.2	Any party may, in whole or in part, release, compound, compromise, waive or postpone, in its absolute discretion, any liability owed to it or right granted to it in this Agreement
by any other party or parties without in any way prejudicing or affecting its rights in respect of that or any other liability or right not so released, compounded, compromised, waived or postponed. 

  

	 	16.3	No single or partial exercise, or failure or delay in exercising any right, power or remedy by any party shall constitute a waiver by that party of, or impair or preclude any
further exercise of, that or any right, power or remedy arising under this Agreement or otherwise. 

  

	17.	Exclusion of warranties 

  

	 	17.1	CDT does not give and nothing contained in this Agreement shall be construed as: 

  

	 	(a)	a warranty or representation by it as to the validity or scope of any patents or patent applications licensed hereunder; 

  

	 	(b)	a warranty of representation by it that any patent applications licensed hereunder will proceed to grant; 

  

 17 

	 	(c)	a warranty or representation by CDT as to the volume or quality of Licensed Products which may be manufactured through the use of the Patents; 

  

	 	(d)	a warranty or representation that Licensed Products can be freely exploited by DOW or any DOW Affiliate and that any manufacture, sale, use, marketing or other disposition of
Licensed Products as contemplated hereunder will be free from infringement of any Intellectual Property of third parties; 

  

	 	(e)	conferring by implication, estoppel or otherwise, upon DOW or any DOW Affiliate, any licence or other right under any patent right or other Intellectual Property except for the
licenses and rights expressly granted hereunder; or 

  

	 	(f)	a representation or warranty as to the efficacy or usefulness of the Patents or that they will produce Licensed Products of satisfactory quality or fit for the purpose for which DOW
or any DOW Affiliate intended. 

  

	18.	Severance 

  
 To the extent that any provision of this Agreement is found by any court or competent authority to be invalid, unlawful or unenforceable in any
jurisdiction, that provision shall be deemed not to be a part of this Agreement, it shall not affect the enforceability of the remainder of this Agreement nor shall it affect the validity, lawfulness or enforceability of that provision in any other
jurisdiction. 
  

	19.	Announcements 

  
 The parties shall make a joint announcement within thirty (30) days of the signature of this Agreement. The text of such announcement shall be agreed by
the parties and it shall not be made public until such agreement is reached. In addition, the parties will use their reasonable endeavours to promote LEP technology for the duration of this Agreement. 
  

	20.	Non-Solicitation 

  
 Neither Party nor their Affiliates may at any time during this Agreement or for a period of twelve (12) months from the expiry or termination of this
Agreement engage, employ or utilise in any capacity, the services of or introduce to another employer either temporarily or permanently, directly or indirectly any person employed by the other Party or its Affiliates, save with the prior permission
of the other Party. Entire Agreement 
  

 18 

 This Agreement sets out the entire agreement and understanding between the parties in respect of the
subject matter of this Agreement and it may not be modified except by an instrument in writing signed by the duly authorised representatives of the parties. 
  
 This Agreement has been signed on the date appearing at the head of page 1. 
  

							
	 Signed by 
	 	)	 	 /s/ David Fyfe

	 	 
	 for and on behalf of
	 	)	 	Chief Executive Officer	 	 
	 Cambridge Display Technologies
	 	)	 	 	 	 
	 Limited
	 	 	 	 	 	 
				
	 Signed by E. F. Gambrell
	 	)	 	 /s/ E. F. Gambrell

	 	 
	 for and on behalf of
	 	)	 	 	 	 
	 The Dow Chemical Company
	 	)	 	 	 	 

  

 19 

 Schedule 1 
  

CDT 003 
 Published as WO 92/03490 on 5 March 1992

  

																	
	 Country

	  	Sub

	  	Status

	  	Case

	  	Application

	  	    Filing Date    

	  	Patent
Number

	  	         Issue        
 Date

	  	    Expiration    

	 AT
	  	E	  	Granted	  	EPC	  	91 915877.4	  	22-Aug-1991	  	E179434	  	28-Apr-1999	  	22-Aug-2011
	 BE
	  	E	  	Granted	  	EPC	  	91 915877.4	  	22-Aug-1991	  	0544795	  	28-Apr-1999	  	22-Aug-2011
	 CA
	  	T	  	Pending	  	PCT	  	2089482	  	22-Aug-1991	  	2089482	  	 	  	22-Aug-2011
	 CH
	  	E	  	Granted	  	EPC	  	91 915877.4	  	22-Aug-1991	  	0544795	  	28-Apr-1999	  	22-Aug-2011
	 DE
	  	E	  	Granted	  	EPC	  	91 915877.4	  	22-Aug-1991	  	69131180.3	  	28-Apr-1999	  	22-Aug-2011
	 DK
	  	E	  	Granted	  	EPC	  	91 915877.4	  	22-Aug-1991	  	0544795	  	28-Apr-1999	  	22-Aug-2011
	 EP
	  	E	  	Granted	  	PCT	  	91 915877.4	  	22-Aug-1991	  	0544795	  	28-Apr-1999	  	22-Aug-2011
	 ES
	  	E	  	Granted	  	EPC	  	91 915877.4	  	22-Aug-1991	  	0544795	  	28-Apr-1999	  	22-Aug-2011
	 FR
	  	E	  	Granted	  	EPC	  	91 915877.4	  	22-Aug-1991	  	0544795	  	28-Apr-1999	  	22-Aug-2011
	 GB
	  	E	  	Granted	  	EPC	  	91 915877.4	  	22-Aug-1991	  	0544795	  	28-Apr-1999	  	22-Aug-2011
	 GR
	  	E	  	Granted	  	EPC	  	91 915877.4	  	22-Aug-1991	  	0544795	  	28-Apr-1999	  	22-Aug-2011
	 HK
	  	R	  	Granted	  	ORD	  	98 111004.4	  	22-Aug-1991	  	1010381	  	11-Aug-2000	  	22-Aug-2011
	 IT
	  	E	  	Granted	  	EPC	  	91 915877.4	  	22-Aug-1991	  	0544795	  	28-Apr-1999	  	22-Aug-2011
	 JP
	  	D1	  	Pending	  	DIV	  	2001-230678	  	30-Jul-2001	  	 	  	 	  	22-Aug-2011
	 JP
	  	T	  	Pending	  	PCT	  	514597/91	  	22-Aug-1991	  	 	  	 	  	22-Aug-2011
	 LU
	  	E	  	Granted	  	EPC	  	91 915877.4	  	22-Aug-1991	  	0544795	  	28-Apr-1999	  	22-Aug-2011
	 NL
	  	E	  	Granted	  	EPC	  	91 915877.4	  	22-Aug-1991	  	0544795	  	28-Apr-1999	  	22-Aug-2011
	 SE
	  	E	  	Granted	  	EPC	  	91 915877.4	  	22-Aug-1991	  	0544795	  	28-Apr-1999	  	22-Aug-2011
	 US
	  	D1	  	Granted	  	DIV	  	80/246,269	  	22-Aug-1991	  	5512654	  	30-Apr-1996	  	24-Aug-2010
	 US
	  	D2	  	Granted	  	DIV	  	08/506,201	  	22-Aug-1991	  	5672678	  	30-Sep-1997	  	24-Aug-2010
	 US
	  	T	  	Granted	  	PCT	  	07/748,777	  	22-Aug-1991	  	5401827	  	28-Mar-1995	  	28-Mar-2012
	  
 CDT 008
 Published as WO 94/29883 on 22 December 1994
  

	 Country

	  	Sub

	  	Status

	  	Case

	  	Application

	  	    Filing Date    

	  	Patent
Number

	  	 Issue
         Date        

	  	    Expiration    

	 DE
	  	T	  	Pending	  	EPC	  	69427909.9-0	  	20-May-1994	  	0704094	  	 	  	20-May-2014
	 EP
	  	T	  	Granted	  	PCT	  	94 915663.2	  	20-May-1994	  	0704094	  	08-Aug-2001	  	20-May-2014
	 GB
	  	T	  	Pending	  	EPC	  	94 915663.2	  	20-May-1994	  	 	  	 	  	20-May-2014
	 NL
	  	TO	  	Pending	  	EPC	  	94 915663.2	  	20-May-1994	  	 	  	 	  	20-May-2014
	 US
	  	 	  	Granted	  	ORD	  	210327	  	18-Mar-1994	  	5514878	  	07-May-1996	  	18-Mar-2014

 CDT 012 
 Published as GB 2296815 on 10 July 1994 
  

																	
	 Country

	  	Sub

	  	Status

	  	Case

	  	Application

	  	Filing Date

	  	 Patent
 Number

	  	 Issue
 Date

	  	Expiration

	 GB
	  	O	  	Granted	  	ORD	  	94 24894.5	  	09-Dec-1994	  	2296815	  	17-Mar-1999	  	09-Dec-2014
	 US
	  	O	  	Granted	  	ORD	  	08/569,710	  	08-Dec-1995	  	5698048	  	16-Dec-1997	  	08-Dec-2015
	  
 CDT
023
 Published as WO96020253 on 4 July 1996
  

	 Country

	  	Sub

	  	Status

	  	Case

	  	Application

	  	Filing Date

	  	 Patent
 Number

	  	 Issue
 Date

	  	Expiration

	 DE
	  	T	  	Granted	  	EPC	  	69518011.8-0	  	18-Jul-1997	  	DE69518011	  	12-Jul-2000	  	18-Jul-2017
	 EP
	  	1	  	Published	  	EDV	  	99 124732.1	  	18-Jul-1997	  	99 124732.1	  	 	  	18-Jul-2017
	 EP
	  	T	  	Granted	  	PCT	  	95 941813.8	  	18-Jul-1997	  	0800563	  	12-Jul-2000	  	18-Jul-2017
	 GB
	  	E	  	Granted	  	EPC	  	95 941813.8	  	18-Jul-1997	  	0800563	  	12-Jul-2000	  	18-JuL-2017
	 JP
	  	T	  	Pending	  	PCT	  	8-520312	  	28-Dec-1995	  	 	  	 	  	18-Jul-2017
	 NL
	  	T	  	Granted	  	EPC	  	95 941813.8	  	18-Jul-1997	  	0800563	  	12-Jul-2000	  	18-JuI-2017
	 US
	  	DI	  	Pending	  	DIV	  	09/561,847	  	28-Apr-2000	  	 	  	 	  	 
	 US
	  	D2	  	Pending	  	DIV	  	09/1561,831	  	28-Apr-2000	  	 	  	 	  	 
	 US
	  	T	  	Abandoned	  	PCT	  	08/1875,049	  	28-Dec-1995	  	 	  	 	  	 
	  
 CDT 038
 Published as WO 98/32783 on 30 July 1998
  

	 Country

	  	Sub

	  	Status

	  	Case

	  	Application

	  	Filing Date

	  	 Patent
 Number

	  	 Issue
 Date

	  	Expiration

	 GB
	  	T	  	Granted	  	PCT	  	99 12582.5	  	26-Jan-1998	  	2335430	  	13-Sep-2000	  	26-Jan-2018
	 US
	  	T	  	Granted	  	PCT	  	09/355,383	  	26-Jan-1998	  	6,153,711	  	28-Nov-2000	  	26-Jan-2018

																	
	 CDT 072
 Published as
WO99/12989 on 18 March 1999
  

	 Country

	  	Sub

	  	Status

	  	Case

	  	Application

	  	Filing Date

	  	Patent
Number

	  	 Issue
 Date

	  	Expiration

	 EP
	  	E	  	Published	  	ORD	  	98 941598.9	  	04 Sep-1998	  	 	  	 	  	04-Sep-2018
	 JP
	  	T	  	Nat. Filed	  	PCT	  	2000-510790	  	04-Sep-1998	  	 	  	 	  	04-Sep-2018
	 US
	  	T	  	Pending	  	ORD	  	09/508,035	  	04-Sep-1998	  	 	  	 	  	04-Sep-2018
	 WO
	  	T	  	Nat. Filed	  	ORD	  	PCTGB98/02	  	04-Sep-1998	  	 	  	 	  	04-Sep-2018
	  
 CDT 048
 Published as WO 99/20711 on 29 April 1999
  

	 Country

	  	Sub

	  	Status

	  	Case

	  	Application

	  	Filing Date

	  	Patent
Number

	  	 Issue
 Date

	  	Expiration

	 EP
	  	T	  	Published	  	PCT	  	98 949124.6	  	21-Oct-1998	  	 	  	 	  	21-Oct-2018
	 JP
	  	T	  	Pending	  	PCT	  	2000-517035	  	21-Oct-1998	  	 	  	 	  	21-Oct-2018
	 US
	  	T	  	Pending	  	PCT	  	09/529,873	  	21-Oct-1998	  	 	  	 	  	21-Oct-2018
	 WO
	  	T	  	Published	  	ORD	  	PCTGB98/03	  	21-Oct-1998	  	 	  	 	  	21-Oct-2018
	  
 CDT 058
 Published as GB 2328442 on 24 February 1999
  

	 Country

	  	Sub

	  	Status

	  	Case

	  	Application

	  	Filing Date

	  	Patent
Number

	  	 Issue
 Date

	  	Expiration

	 GB
	  	O	  	Granted	  	ORD	  	98 06947.9	  	31-Mar-1998	  	2328442	  	05-Sep-2001	  	31-Mar-2018
	 US
	  	O	  	Pending	  	ORD	  	09/283,127	  	31-Mar-1999	  	 	  	 	  	31-Mar-2019
	  
 CDT 074
 Published as GB 2340304 on 16 February 2000
  

	 Country

	  	Sub

	  	Status

	  	Case

	  	Application

	  	Filing Date

	  	Patent
Number

	  	 Issue
 Date

	  	Expiration

	 GB
	  	O	  	Published	  	ORD	  	98 18376.7	  	21-Aug-1998	  	 	  	 	  	21-Aug-2018
	 US
	  	O	  	Pending	  	ORD	  	09/377,079	  	19-Aug-1999	  	 	  	 	  	31-Aug-2019

																	
	 CDT 089
 Published as
WO00/53656 on 14 September 2000
  
	  	 
	 Country

	  	Sub

	  	Status

	  	Case

	  	Application

	  	 Filing
 Date

	  	Patent
Number

	  	 Issue
 Date

	  	Expiration

	 CA
	  	T	  	Pending	  	PCT	  	 	  	03-Mar-2000	  	 	  	 	  	03-Mar-2020
	 CN
	  	T	  	Pending	  	PCT	  	 	  	03-Mar-2000	  	 	  	 	  	03-Mar-2020
	 EP
	  	T	  	Pending	  	PCT	  	00 907788.4	  	03-Mar-2000	  	 	  	 	  	03-Mar-2020
	 JP
	  	T	  	Pending	  	PCT	  	 	  	03-Mar-2000	  	 	  	 	  	03-Mar-2020
	 KR
	  	T	  	Pending	  	PCT	  	 	  	03-Mar-2000	  	 	  	 	  	03-Mar-2020
	 US
	  	N	  	Pending	  	ORD	  	09/518,991	  	03-Mar-2000	  	 	  	 	  	03-Mar-2020
	 US
	  	P	  	Pending	  	PRO	  	60/160,953	  	22-Oct-1999	  	 	  	 	  	 
	 WO
	  	T	  	Published	  	ORD	  	PCTGB00/00	  	03-Mar-2000	  	 	  	 	  	 
	 	  	 	  	 	  	 	  	 	  	 	  	 	  	 	  	03-Mar-2020
	  
 CDT 108
 Published as WO01/07502 on 1 February 2001
  
	  	 
	 Country

	  	Sub

	  	Status

	  	Case

	  	Application

	  	 Filing
 Date

	  	Patent
Number

	  	 Issue
 Date

	  	 Expiration

	 GB
	  	O	  	Abandoned	  	ORD	  	99 17424.5	  	23-JuI-1999	  	 	  	 	  	 
	 WO
	  	T	  	Published	  	ORD	  	PCTGB00/02	  	24-Ju1-2000	  	 	  	 	  	24-JuI-2020
	  
 CDT 200
 Published as WO 00/60612 on 12 October 2000
  
	  	 
	 Country

	  	Sub

	  	Status

	  	Case

	  	Application

	  	 Filing
 Date

	  	Patent
Number

	  	 Issue
 Date

	  	 Expiration

	 CN
	  	T	  	Pending	  	PCT	  	 	  	05-Apr-2000	  	 	  	 	  	05-Apr-2020
	 EP
	  	T	  	Pending	  	PCT	  	 	  	05-Apr-2000	  	 	  	 	  	05-Apr-2020
	 JP
	  	T	  	Pending	  	PCT	  	 	  	05-Apr-2000	  	 	  	 	  	05-Apr-2020
	 KR
	  	T	  	Pending	  	PCT	  	 	  	05-Apr-2000	  	 	  	 	  	05-Apr-2020
	 US
	  	T	  	Pending	  	PCT	  	 	  	05-Apr-2000	  	 	  	 	  	05-Apr-2020

																	
	 CDT 175
 Published as
WO01/49768 on 12 July 2001
  
	  	 
	 Country

	  	Sub

	  	Status

	  	Case

	  	Application

	  	 Filing
 Date

	  	Patent
Number

	  	 Issue
 Date

	  	Expiration

	 TW
	  	N	  	Pending	  	ORD	  	90101326	  	19 Jan-2001	  	 	  	 	  	19-Jan-2021
	 US
	  	P	  	Pending	  	PRO	  	60/185,895	  	29-Feb-2000	  	 	  	 	  	 
	 WO
	  	T	  	Published	  	ORD	  	PCTGB01/00	  	04-Jan-2001	  	 	  	 	  	04-Jan-2021
	  
 CDT 088
 Published as WO01/49769 on 12 July 2001
  
	  	 
	 Country

	  	Sub

	  	Status

	  	Case

	  	Application

	  	 Filing
 Date

	  	Patent
Number

	  	 Issue
 Date

	  	Expiration

	 TW
	  	O	  	Pending	  	ORD	  	90101328	  	19-Jan-2001	  	 	  	 	  	19-Jan-2021
	 US
	  	O	  	Pending	  	ORD	  	09/754, 744	  	04-Jan-2001	  	 	  	 	  	04-Jan-2021
	 WO
	  	T	  	Published	  	ORD	  	PCTGB01/00	  	04-Jan-2001	  	 	  	 	  	04-Jan-2021
	  
 CDT 084
 Published as WO 01/62822 on 30 Aug 2001
  
	  	 
	 Country

	  	Sub

	  	Status

	  	Case

	  	Application

	  	 Filing
 Date

	  	Patent
Number

	  	 Issue
 Date

	  	Expiration

	 TW
	  	O	  	Pending	  	ORD	  	90108644	  	11-Apr-2001	  	 	  	 	  	11-Apr-2021
	 WO
	  	O	  	Published	  	ORD	  	PCTGB01/00	  	26-Feb-2001	  	 	  	 	  	26-Feb-2021
	  
 CDT 208
 Published as WO 01/62869 on 30 August 2001
  
	  	 
	 Country

	  	Sub

	  	Status

	  	Case

	  	Application

	  	 Filing
 Date

	  	Patent
Number

	  	 Issue
 Date

	  	Expiration

	 TW
	  	 	  	Pending	  	 	  	 	  	To be advised	  	 	  	 	  	 
	 WO
	  	T	  	Published	  	ORD	  	PCTGB01/00	  	26-Feb-2001	  	 	  	 	  	26-Feb-2021

 Schedule 2 
  

THE LICENCE 
  
 The terms of this license include: 
  

	•	$[**] up-front fee for manufacture of display devices of up to [**] 

  

	•	Additional up-front fees for each step-up in display resolution, vis [**], according to the following formula (fee not to be exceeded): 

  

	
	 [**]
 [**]

  
  

	•	[**] 

  

	•	Maximum royalty rate of [**]% [**] 

  

	•	Maximum royalty rate of [**]% [**] 

  

	•	Maximum royalty rate of [**]% [**] 

  

	•	Published Intellectual Property owned by CDT allowing the DOW to make polymer OLED displays is available for use within the above royalty schedule 

  

	•	DOW retains the right to make polymer OLED displays, so long as the foregoing terms and conditions are adhered to by DOW 

  

	•	The licensed party (DOW or JV) will grant back to CDT a license under the licensed party’s published Intellectual Property developed under this license and relating to devices
or processes required for making polymer OLEDsPatent and Know-How License, dated December 14, 2001

 Exhibit 10.19 
  
 PATENT AND KNOW-HOW LICENCE 
  

CAMBRIDGE DISPLAY TECHNOLOGY LIMITED (1) 
  
 AND 
  
 COVION ORGANIC SEMICONDUCTORS GMBH (2) 
  
 CONFIDENTIAL TREATMENT REQUESTED: INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED FROM THIS DOCUMENT. SUCH OMISSIONS ARE NOTED BY “[**]”. AN UNREDACTED VERSION OF THIS DOCUMENT
HAS BEEN SUBMITTED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION. 

 PATENT AND KNOW HOW LICENCE 
  
 THIS AGREEMENT is made the 14th day of December 2001 between: 
  

	(1)	CAMBRIDGE DISPLAY TECHNOLOGY LIMITED a company incorporated in England whose registered office is situated at Greenwich House, Madingley Rise, Madingley Road, Cambridge,
England (“CDT”); and 

  

	(2)	COVION ORGANIC SEMICONDUCTORS GMBH, a company incorporated in Germany whose principal place of business is situated at Industriepark Hoechst, Gebaude G864, D-65926, Frankfurt
am Main, Germany (“Covion”). 

  
 RECITALS:

  

	(A)	CDT is the registered proprietor of certain patents and patent applications and/or has rights to, or may be able to obtain rights to, certain other patents and patent applications,
in either case relating to organic semiconductors. 

  

	(B)	CDT has developed and owns certain methods and know-how that it believes are secret, technical and useful in the exploitation of organic semiconductors. 

  

	(C)	CDT and Covion have agreed that CDT should grant Covion licences under certain patents and patent applications (and seek to grant Covion sub-licences under certain other patents
and/or patent applications) and the right to use the methods and know-how on, and subject to, the terms and conditions set out below. 

  
 IT IS HEREBY AGREED AS FOLLOWS: 
  

	1.	DEFINITIONS 

  

	1.1	In this Agreement including its Schedules, the headings are included for ease of reference only and shall not affect its interpretation and the following terms shall have the
following meanings unless the context otherwise requires: 

  
 “Affiliate” means, at the relevant time, any business entity which controls, is controlled by or is under common control with the business entity referred to but in each case only for so long as such
control or common control relationship exists; for the purposes of this definition a business entity shall be deemed to “control” another business entity if it owns, directly or indirectly, in excess of 50% of the outstanding voting
securities or capital stock of such business entity or other comparable equity or ownership interest with respect to a business entity other than a corporation. 

 “Assigned Patent” means patent application WO 00/55927 (together with the rights to all
patents claiming priority therefrom including associated or national regional patents and continuations thereof) which patent application includes the claims listed in Schedule 1 to this Agreement. 
  
 “Avecia Group Company” means Avecia Limited (a company
incorporated in England with company number 3730853) or any Affiliate of Avecia Limited. 
  
 “CDT Group Company” means CDT or any Affiliate of CDT. 
  
 “Confidential Information” means all confidential information disclosed by one party or any of its Affiliates (“the Disclosing
Party”) to the other party or any of its Affiliates (“the Receiving Party”) pursuant to this Agreement in written, verbal or any other form, including, without limitation, data, know-how, formulae, compositions, designs,
photographs, drawings, specifications, software programs, samples, any product made using the samples and any other material bearing or incorporating any information relating to such information. 
  
 “Contract Research Agreement” means the contract research
agreement of even date herewith between CDT International Limited and Covion 
  
 “Covion Group Company” means Covion or any Affiliate of Covion. 
  
 “Covion Licensee” means any Covion Group Company, any Avecia Group Company, any Relevant Joint Venture of any Covion Group Company and/or
any Relevant Joint Venture of any Avecia Group Company. 
  
 “Covion OLEM Products” means conjugated polymeric OLEMs (other than PLEMs) or formulations containing conjugated polymeric OLEMs (other than PLEMs) sold pursuant to a supply agreement for use in the Field. 
  
 “Covion OSC Products” means organic semiconductors or
formulations containing organic semiconductors sold pursuant to a supply agreement for use outside the Field where the sale or any other aspect of the exploitation of such organic semiconductors or formulations containing organic semiconductors by
Covion or any Covion Licensee or by a direct customer of Covion or any Covion Licensee has taken place in a country in which such sale or other aspect of the exploitation falls within any of the then still valid claims licensed to Covion under a
Patent covering that country in accordance with this Agreement or falls within any of: 
  

	 	(a)	the then still valid claims in a patent covering that country owned by Covion for an invention covered by Clause 7.5 of the Contract Research Agreement; or 

 

 2 

	 	(b)	the know-how owned by Covion for an invention which is considered to be equivalent to a patent in that country pursuant to Clause 7.5 of the Contract Research Agreement.

  
 “Covion Products” means Covion
OLEM Products and/or Covion OSC Products. 
  
 “Devices” means devices containing organic semiconductors. 
  
 “Dow” means Dow Chemical Corporation whose principal place of business is situated at 2030 Building, Midland, M1 48674, USA; and “Dow Group Company” means Dow or any Affiliate of Dow;

  
 “Effective Date” means the date of this
Agreement. 
  
 “Existing Know-How” means all
know-how, experience, drawings and all other technical information of any CDT Group Company (or to which any CDT Group Company has relevant rights) that was developed prior to the Effective Date and which: 
  

	 	(i)	relates to organic semiconductors generally (as distinct from specific classes or types of organic semiconductors), Relevant Materials, formulations containing organic
semiconductors generally (as distinct from specific classes or types of organic semiconductors), formulations containing Relevant Materials and the uses of organic semiconductors generally (as distinct from specific classes or types of organic
semiconductors), Relevant Materials and/or such formulations (including, without limitation, processes for the manufacture of any of the foregoing) but not to the extent it relates to or concerns the design, development or fabrication of Devices;

  

	 	(ii)	might reasonably be of commercial interest in the design, manufacture or supply of organic semiconductors generally (as distinct from specific classes or types of organic
semiconductors), Relevant Materials and/or such formulations; 

  

	 	(iii)	as a body or in the precise configuration and assembly of its components is not generally known or easily accessible; and 

  

	 	(iv)	was not developed or otherwise acquired pursuant to or as part of a preexisting relevant business by a CDT Group Company at any time before it became an Affiliate of CDT.

  

 3 

 “Existing Patents” means the patents and/or patent applications owned or to be owned by
any CDT Group Company or to which any CDT Group Company has/will have relevant rights which enable such CDT Group Company to license/sub-license third parties and which in either case are for inventions made prior to the Effective Date which were
not made or otherwise acquired pursuant to or as part of a pre-existing relevant business by a CDT Group Company at any time before it became an Affiliate of CDT. 
  
 “exploitation” means manufacture, import, keeping, use and/or sale (including in relation to any such
activity offering to do any of these). 
  
 “Field” means the field of displays and lighting. 
  
 “Future Know-How” means all know-how, experience, drawings and all other technical information of any CDT Group Company (or to which any CDT Group Company has relevant rights) that is developed on or
after the Effective Date and prior to the termination or expiry of the Contract Research Agreement (disregarding for these purposes clause 13.3 of that agreement) and which: 
  

	 	(i)	relates to organic semiconductors generally (as distinct from specific classes or types of organic semiconductors), Relevant Materials, formulations containing organic
semiconductors generally (as distinct from specific classes or types of organic semiconductors), formulations containing Relevant Materials and the uses of organic semiconductors generally (as distinct from specific classes or types of organic
semiconductors), Relevant Materials and/or such formulations (including, without limitation, processes for the manufacture of any of the foregoing) but not to the extent it relates to or concerns the design, development or fabrication of Devices;

  

	 	(ii)	is developed independently of any work carried out by any CDT Group Company, or confidential information of Covion disclosed to any CDT Group Company, pursuant to the Contract
Research Agreement; 

  

	 	(iii)	might reasonably be of commercial interest in the design, manufacture or supply of organic semiconductors generally (as distinct from specific classes or types of organic
semiconductors), Relevant Materials and/or such formulations; 

  

	 	(iv)	which as a body or in the precise configuration and assembly of its components is not generally known or easily accessible; and 

  

 4 

	 	(v)	is not developed or otherwise acquired pursuant to or as part of a pre-existing relevant business by a CDT Group Company at any time before it became an Affiliate of CDT.

  
 “Future Patents” means the
patents and/or patent applications to be owned by any CDT Group Company or to which any CDT Group Company will have relevant rights which enable any CDT Group Company to license/sub-license third parties and which in either case are for inventions
made (a) on or after the Effective Date which were not made or otherwise acquired pursuant to or as part of a pre-existing relevant business by a CDT Group Company at any time before it became an Affiliate of CDT; and (b) prior to the termination or
expiry of the Contract Research Agreement independently of any work carried out by any CDT Group Company, or confidential information of Covion disclosed to any CDT Group Company pursuant to the Contract Research Agreement. 
  
 “Know-How” means the Existing Know-How and/or the Future
Know-How. 
  
 “Net Sales Value” means the gross
invoice price for sales of Covion Products on an arm’s length basis by Covion or any Covion Licensee to any third party (i.e. an entity other than Covion or a Covion Licensee), less: 
  

	 	(i)	the cost of packaging (not forming part of the Covion Products), transportation and insurance; 

  

	 	(ii)	commissions, early payment discounts (but only where these are in accordance with local business custom and practice), trade discounts or quantity discounts actually granted;

  

	 	(iii)	allowances or credits actually granted to customers on account of settlement of complaints, returns and replacements; and 

  

	 	(iv)	sales taxes and/or other taxes and/or tariff duties directly imposed on sales of Covion Products. 

  
 Where Covion Products are sold other than on an arm’s length basis to a third party (ie. an entity other than Covion or
a Covion Licensee), the Net Sales Value shall be deemed to be the average gross invoice price obtained by Covion or the relevant Covion Licensee (as the case may be) for sales on an arm’s length basis over the six months immediately preceding
the transaction in question less those items specified above. 
  
 “OLEMs” means organic light-emitting materials. 
  

 5 

 “Patents” means the Existing Patents and/or the Future Patents and/or the Assigned
Patent. 
  
 “PLEMs” means (a) Polyfluorenes; (b)
solid compositions containing Polyfluorenes in an amount of at least one percent (1%) by weight; and (c) solutions containing Polyfluorenes including formulations for ink jet printing; for the purposes of this definition
“Polyfluorenes” means any polymer having substituted or unsubstituted 2,7 linked fluorene mer units but does not include polymer where all the fluorene units are spirofluorenes or indenofluorenes. 
  
 “Relevant Materials” means specific classes or types of
organic semiconductors other than PLEMs. 
  
 “Relevant
Joint Venture” means any joint venture in which the business entity referred to has at least a 50% interest in the outstanding voting securities or capital stock of such joint venture or any other comparable equity or ownership interest
with respect to a business entity other than a corporation. 
  
 “Royalty Income” means any income (after deduction of any taxes imposed directly on such income) from sales of organic semiconductors obtained by Covion or any Covion Licensee from the licensing to any third party (i.e. an
entity which is not a Covion Licensee) of any patent owned at any time by Covion for an invention covered by Clause 7.5 of the Contract Research Agreement or any know-how owned at any time by Covion for an invention which is considered to be
equivalent to a patent in certain countries pursuant to Clause 7.5 of the Contract Research Agreement. 
  
 “SEC” means Seiko Epson Corporation, a company incorporated in Japan whose registered office is situated at 3-3-5 Owa, Suwa-Shi,
Nagano-ken 392, Japan. 
  
 “Sumitomo” means
Sumitomo Chemicals Limited, a company incorporated in Japan whose registered office is situated at 27-1 Shinkawa 2-chome, Chuo-ku, Tokyo 104-8260, Japan; and “Sumitomo Group Company” means Sumitomo or any Affiliate of Sumitomo.

  
 “Territory” means in relation to both the
Patents and the Know-How, worldwide. 
  

	1.2	A reference to any party to this Agreement shall include a reference to its legal successors and permitted assignees. 

  

	1.3	References to recitals, clauses, paragraphs, and schedules are to recitals, clauses, paragraphs and schedules to this Agreement. 

  

 6 

	1.4	The Schedules form part of this Agreement and shall have the same force and effect as if expressly set out in the body of the Agreement and any reference to the Agreement shall
include the Schedules. 

  

	1.5	References to writing shall include any mode of reproducing words in a legible and non-transitory form 

  

	1.6	References to “£” and “pounds sterling” are references to the currency of the United Kingdom. 

  

	1.7	The term “licence” in this Agreement shall where CDT can only grant a sub-licence mean a “sub-licence”. 

  

	2.	GRANT OF LICENCES/RIGHTS TO THIRD PARTIES AND CDT CONTINUING RESEARCH ETC. RIGHTS 

  

	2.1	CDT has entered into an agreement with Dow under which CDT has: 

  

	 	2.1.1	exclusively licensed to Dow under the Existing Patents the claims which relate specifically to PLEMs, the claims to formulations containing PLEMs and the claims to the uses of PLEMs
and such formulations, (including, without limitation, claims to processes for the manufacture of PLEMs and such formulations and in particular claims to all process technology relating to the Suzuki coupling reaction for use in making PLEMs) but
not (in relation to any or all of the foregoing) any such claim to the extent that it relates to or concerns the design, development or fabrication of Devices; 

  

	 	2.1.2	granted to Dow an option to take a non-exclusive licence under the Existing Patents which had been published as at 1st June 2001: 

  

	 	2.1.2.1	of the claims relating to Relevant Materials, the claims to formulations containing Relevant Materials and the claims to the uses of Relevant Materials and/or such formulations
(including, without limitation, claims to processes for the manufacture of any of the foregoing); and 

  

	 	2.1.2.2	of the claims to organic semiconductors generally (as distinct from specific classes or types of organic semiconductors), the claims to formulations containing organic
semiconductors generally (as distinct from specific classes or types of organic semiconductors) and the claims to the uses of organic semiconductors generally (as distinct from specific classes or types of organic semiconductors) and such
formulations, (including, without limitation, claims to 

  

 7 

	 	    	processes for the manufacture of organic semiconductors generally (as distinct from specific classes or types of organic semiconductors) and such formulations),

  

	 	    	but not (in relation to any or all of the foregoing) of any such claim to the extent that it relates to or concerns the design, development or fabrication of Devices;

  

	 	2.1.3	exclusively licensed to Dow its know-how as at the Effective Date and in the future which relates specifically to PLEMs, to formulations containing PLEMs and to the uses of PLEMs
and such formulations, (including, without limitation, processes for the manufacture of PLEMs and such formulations and in particular all process technology relating to the Suzuki coupling reaction for use in making PLEMs) but not (in relation to
any or all of the foregoing) any such know-how to the extent that it relates to or concerns the design, development or fabrication of Devices; 

  

	 	2.1.4	non-exclusively licensed to Dow such of its know-how both at the Effective Date and in the future as is necessary to exploit the Existing Patents for all process technology relating
to the Suzuki coupling reaction for use in making Relevant Materials but not (in relation to any or all of the foregoing) any such know-how to the extent that it relates to or concerns the design, development or fabrication of Devices; and

  

	 	2.1.5	non-exclusively licensed to Dow under the Existing Patents: 

  

	 	2.1.5.1	the claims to spirofluorenes and/or indenofluorenes specifically, the claims to formulations containing spirofluorenes and/or indenofluorenes specifically) and the claims to the
uses of spirofluorenes and/or indenofluorenes specifically and such formulations, (including, without limitation, claims to processes for the manufacture of spirofluorenes and/or indenofluorenes specifically); and 

  

	 	2.1.5.2	the claims to all process technology relating to the Suzuki coupling reaction for use in making Relevant Materials, 

  

	 	    	but not (in relation to any or all of the foregoing) any such claim to the extent that it relates to or concerns the design, development or fabrication of Devices.

  

	 	    	As part of such agreement CDT has assigned to Dow the Assigned Patent. 

  

 8 

	2.2	CDT has entered into an agreement with Sumitomo under which CDT has: 

  

	 	2.2.1	non-exclusively licensed to Sumitomo under the Existing Patents which had been published as at 8th July 2001: 

  

	 	2.2.1.1	the claims relating to Relevant Materials, the claims to formulations containing Relevant Materials and the claims to the uses of Relevant Materials and/or such formulations
(including, without limitation, claims to processes for the manufacture of any of the foregoing); and 

  

	 	2.2.1.2	the claims to organic semiconductors generally (as distinct from specific classes or types of organic semiconductors), the claims to formulations containing organic semiconductors
generally (as distinct from specific classes or types of organic semiconductors) and the claims to the uses of organic semiconductors generally (as distinct from specific classes or types of organic semiconductors) and such formulations, (including,
without limitation, claims to processes for the manufacture of organic semiconductors generally (as distinct from specific classes or types of organic semiconductors) and such formulations), 

  

	 	    	but not (in relation to any or all of the foregoing) any such claim to the extent that it relates to or concerns the design, development or fabrication of Devices;

  

	 	2.2.2	non-exclusively licensed to Sumitomo its know-how as at 8th July 2001 which relates to: 

  

	 	2.2.2.1	Relevant Materials, formulations containing Relevant Materials and the uses of Relevant Materials and/or such formulations (including, without limitation, processes for the
manufacture of any of the foregoing); and 

  

	 	2.2.2.2	organic semiconductors generally (as distinct from specific classes or types of organic semiconductors), to formulations containing organic semiconductors generally (as distinct
from specific classes or types of organic semiconductors) and to the uses of organic semiconductors generally (as distinct from specific classes or types of organic semiconductors) and such formulations, (including, without limitation, processes for
the manufacture of organic semiconductors generally (as distinct from specific classes or types of organic semiconductors) and such formulations) 

  

 9 

	 	    	but not (in relation to any or all of the foregoing) any such know-how to the extent that it relates to or concerns the design, development or fabrication of Devices.

  
 As part of such agreement CDT is also obliged
to give some general technical assistance in Sumitomo’s development of red, green, blue and white OLEMs which CDT warrants to Covion will consist only of providing device testing and suggestions for optimising device architecture for use with
polymers supplied by Sumitomo and dissolved in solvents by CDT. For the avoidance of doubt CDT undertakes to Covion that CDT will not provide Sumitomo with suggestions for chemical modification of OLEMs. 
  

	2.3	CDT hereby warrants that Dow has no rights under the non-exclusive licences referred to in Clause 2.1 to sub-license third parties other than Dow Group Companies, Relevant Joint
Ventures of any Dow Group Company and toll manufacturers. CDT hereby warrants that Sumitomo have no rights under the non-exclusive licences referred to in Clause 2.2 to sub-license third parties other than Sumitomo Group Companies, Relevant Joint
Ventures of any Sumitomo Group Company and toll manufacturers (save for those based in the Peoples Republic of China) (however for these purposes only a Sumitomo Group Company shall be deemed to be any corporation, company or other entity fifty
percent (50%) or more of which is owned by or controlled by or under common control with Sumitomo. 

  

	2.4	CDT hereby undertakes not to initiate any discussions with Dow with regard to exercise of the option granted to Dow referred to in Clause 2.1.2. Should Dow exercise the said option
and take a non-exclusive licence under the Existing Patents which had been published as at 1st June 2001 then CDT
undertakes to reduce the aggregate royalties payable by Covion under this Agreement and the Contract Research Agreement (if any) in respect of any Relevant Material specifically mentioned in an Existing Patent published as at 1st June 2001 which is the same, or substantially the same, as a Relevant Material being sold by Dow which is covered by the above
licence to the same level as those being paid to CDT by Dow for such material under the above licence. 

  

	2.5	Notwithstanding the grant of the exclusive and non-exclusive licences referred to Clauses 3 to 8 below, Covion acknowledges and agrees that CDT shall be entitled to carry out on its
own behalf only, research and development (but not exploitation unless allowed in accordance with the provisions of Clause 8) relating to the application of any of the technology the subject of such licences outside of the Field and to promote or
otherwise market the existence (but not the detail) of such technology in general terms throughout the world. 

  

 10 

	3.	LICENCE/RIGHTS TO RELEVANT MATERIALS 

  

	3.1	CDT hereby grants to Covion an exclusive (save for the non-exclusive licence granted to Dow referred to in Clauses 2.1.5) licence under the Existing Patents to exploit in any manner
in the Territory during the term of this Agreement: 

  

	 	3.1.1	all claims relating to Relevant Materials which are not listed in Schedules 3 and/or 4 to this Agreement and all claims to formulations containing Relevant Materials which are not
listed in Schedules 3 and/or 4 to this Agreement (including, without limitation, claims to processes for the manufacture of any of the foregoing); and 

  

	 	3.1.2	all claims (if any) to organic semiconductors generally (as distinct from specific classes or types of organic semiconductors) which are not listed in Schedules 3 and/or 4 to this
Agreement and all claims (if any) to formulations containing organic semiconductors generally (as distinct from specific classes or types of organic semiconductors) which are not listed in Schedules 3 and/or 4 to this Agreement (including, without
limitation, claims to processes for the manufacture of any of the foregoing), 

  
 but not (in relation to any or all of the foregoing) any such claim to the extent that it relates to or concerns the design, development or fabrication of Devices. 
  

	3.2	The claims licensed to Covion pursuant to Clause 3.1 shall include but not be limited to those claims listed in Schedule 2 to this Agreement (for the avoidance of doubt only claims
from Existing Patents that have been published as at the Effective Date are included in Schedule 2). The Existing Patents referred to in Clause 5.1 are specifically excluded from the provisions of this Clause 3. 

  

	3.3	CDT hereby grants to Covion a non-exclusive licence under the Existing Patents to exploit in any manner in the Territory during the term of this Agreement any claims under the
Existing Patents not licensed to Covion pursuant to Clause 3.1 or Clause 3.5 but which make reference to any Relevant Materials and/or formulations containing Relevant Materials which are the subject of the licences referred to in Clause 3.1 or
Clause 3.5 PROVIDED ALWAYS THAT where any such claim relates to or concerns the design, development or fabrication of Devices this licence shall only apply to such claim where such claim (as finally granted) is to an already known (at the date the
relevant patent application is filed) Device comprising a new Relevant Material and/or new formulation containing a 

  

 11 

 Relevant Material (i.e. where the only inventive part of the claim is the presence of the new Relevant
Material and/or new formulation containing a Relevant Material). The claims licensed to Covion pursuant to this Clause 3.3 shall include but not be limited to those claims listed in Schedule 6 to this Agreement SUBJECT ALWAYS to the above proviso
(for the avoidance of doubt only claims from Existing Patents that have been published as at the Effective Date are included in Schedule 6). 
  

	3.4	Where the Existing Patents referred to in Clause 3.1 and/or Clause 3.3 are not solely owned by CDT or are owned by third parties but CDT has relevant rights thereunder which enable
them to license/sub-license Covion in the manner specified in Clause 3.1 and/or Clause 3.3 then, where CDT has to pay royalties or any other form of monetary consideration to a relevant third party for those rights and such royalties or other
consideration are significant in the context of the royalties payable by Covion to CDT under Clause 11, the parties shall be under an obligation to discuss and seek to agree in good faith negotiations, an equitable basis for the allocation between
CDT and Covion of such royalties or other consideration. If no agreement can be reached within a reasonable period of time then those Existing Patents to which such discussions relate shall not form part of the Existing Patents licensed/sub-licensed
to Covion in accordance with Clause 3.1 and/or Clause 3.3. CDT hereby warrants that as at the Effective Date it is not aware of any Existing Patents referred to in Clause 3.1 and/or Clause 3.3 where CDT is obliged to pay royalties or other
consideration for the granting of the licences referred to in Clause 3.1 and/or Clause 3.3. 

  

	3.5	CDT hereby grants to Covion an exclusive (save for those non-exclusive licences granted to Dow and Sumitomo referred to in Clauses 2.1.5 and 2.2.1 and the option to take a
non-exclusive licence granted to Dow referred to in Clause 2.1.2) licence under the Existing Patents to exploit in any manner in the Territory during the term of this Agreement all claims listed in Schedules 3 and/or 4 to this Agreement.

  

	3.6	In respect of any claims which are the subject of the licences referred to in Clause 3.1, Clause 3.3 or Clause 3.5, CDT hereby undertakes not to assert any such claims against any
customer of Covion or any Covion Licensee or any third party purchasing a product containing any Relevant Materials from such customer where such customer has purchased the Relevant Materials in question (or a formulation containing such Relevant
Materials) from Covion or any Covion Licensee. In respect of any claims that relate to or concern the design, development or fabrication of Devices which are not licensed to Covion pursuant to Clause 3.3, CDT hereby undertakes not to assert any such
claims against any customer of Covion or any Covion Licensee or any third party purchasing a product containing any Relevant Materials from such customer where such 

  

 12 

 customer has purchased the Relevant Materials in question (or a formulation containing such Relevant
Materials) from Covion or any Covion Licensee, provided that such customer has obtained an appropriate licence from CDT or it is manufacturing Devices otherwise than for sale or other commercial exploitation. 
  

	4.	[**] 

  

	4.1	[**] 

  

	4.2	CDT hereby undertakes not to grant a licence of the claims listed in Schedule 1 to any third party but Covion acknowledges that CDT has already granted a licence to Sumitomo in
respect of those claims listed in Schedule 1 as part of the non-exclusive licence to Sumitomo referred to in Clause 2.2.2. 

  

	4.3	[**] 

  

	4.4	[**] 

  

	4.5	[**] 

  

 13 

	5.	LICENCE/RIGHTS TO SEC PATENTS 

  

	5.1	CDT hereby undertakes to use all reasonable endeavours to obtain agreement from SEC to the grant to Covion by CDT (and/or if necessary SEC) of a non-exclusive licence under the
Existing Patents jointly owned by CDT and SEC or owned by SEC (but under which CDT has/will have relevant rights which enable CDT to licence third parties) to exploit in any manner in the Territory during the term of this Agreement:

  

	 	5.1.1	all claims relating to Relevant Materials, all claims to formulations containing Relevant Materials and all claims to the uses of Relevant Materials and/or such formulations
(including, without limitation, claims to processes for the manufacture of any of the foregoing); and 

  

	 	5.1.2	all claims to organic semiconductors generally (as distinct from specific classes or types of organic semiconductors), all claims to formulations containing organic semiconductors
generally (as distinct from specific classes or types of organic semiconductors) and all claims to the uses of organic semiconductors generally (as distinct from specific classes or types of organic semiconductors) and/or such formulations
(including, without limitation, claims to processes for the manufacture of any of the foregoing), but not (in relation to any or all of the foregoing) any such claim to the extent that it relates to or concerns the design, development or fabrication
of Devices. 

  

 14 

	5.2	The claims referred to in Clause 5.1 shall include but not be limited to those claims listed in Schedule 5 to this Agreement (for the avoidance of doubt only claims from Existing
Patents that have been published as at the Effective Date are included in Schedule 5). 

  

	5.3	CDT hereby undertakes to use all reasonable endeavours to obtain agreement from SEC to the grant to Covion by CDT (and/or if necessary SEC) of a non-exclusive licence under the
Existing Patents jointly owned by CDT and SEC or owned by SEC (but under which CDT has/will have relevant rights which enable CDT to licence third parties) to exploit in any manner in the Territory during the term of this Agreement any claims under
the Existing Patents jointly owned by CDT and SEC or owned by SEC (but under which CDT has/will have relevant rights which enable CDT to licence third parties) not the subject of Clause 5.1 but which make reference to any Relevant Materials and/or
formulations containing Relevant Materials which are the subject of Clause 5.1 PROVIDED ALWAYS THAT where any such claim relates to or concerns the design, development or fabrication of Devices this licence shall only apply to such claim where such
claim (as finally granted) is to an already known (at the date the relevant patent application is filed) Device comprising a new Relevant Material and/or new formulation containing a Relevant Material (ie. where the only inventive part of the claim
is the presence of the new Relevant Material and/or new formulation containing a Relevant Material). The claims referred to in this Clause 5.3 shall include but not be limited to those claims listed in Schedule 7 to this Agreement SUBJECT ALWAYS to
the above proviso (for the avoidance of doubt only claims from Existing Patents that have been published as at the Effective Date are included in Schedule 7). 

  

	5.4	Where CDT has to pay royalties or any other form of monetary consideration to SEC to obtain SEC’s agreement to the grant of the licences referred to in Clause 5.1 and/or Clause
5.3 under any of the Existing Patents and such royalties or other consideration are significant in the context of the royalties payable by Covion to CDT under Clause 11, the parties shall be under an obligation to discuss and seek to agree in good
faith negotiations, an equitable basis for the allocation between CDT and Covion of such royalties or other consideration. If no agreement can be reached within a reasonable period of time then those Existing Patents to which such discussions relate
shall not form part of the Existing Patents which CDT shall be obliged to use all reasonable endeavours to obtain a licence thereof for Covion in accordance with Clause 5.1 and/or Clause 5.3. CDT hereby warrants that as at the Effective Date it is
not aware of any Existing Patents referred to in Clause 5.1 and/or Clause 5.3 where CDT is obliged to pay royalties or other consideration for obtaining SEC’s agreement to the granting of the licence referred to in Clause 5.1 and/or Clause 5.3.

  

 15 

	5.5	If SEC’s agreement is obtained to the granting of the licence referred to in Clause 5.1 and/or Clause 5.3 then CDT shall procure the granting of such licence to Covion as soon
as reasonably practicable thereafter. 

  

	5.6	In respect of any claims which are the subject of the licence referred to in Clause 5.5, CDT hereby undertakes, and shall use all reasonable endeavours to ensure that SEC shall
undertake, not to assert any such claims against any customer of Covion or any Covion Licensee or any third party purchasing a product containing any Relevant Materials from such customer where such customer has purchased the Relevant Materials in
question (or a formulation containing such Relevant Materials) from Covion or any Covion Licensee. In respect of any claims that relate to or concern the design, development or fabrication of Devices which are not licensed to Covion pursuant to the
licence referred to in Clause 5.5, CDT hereby undertakes, and shall use all reasonable endeavours to ensure that SEC shall undertake, not to assert any such claims against any customer of Covion or any Covion Licensee or any third party purchasing a
product containing any Relevant Materials from such customer where such customer has purchased the Relevant Materials in question (or a formulation containing such Relevant Materials) from Covion or any Covion Licensee, provided that such customer
has obtained an appropriate licence from CDT and/or SEC, as relevant in the circumstances, or it is manufacturing Devices otherwise than for sale or other commercial exploitation. 

  

	6.	LICENCE/RIGHTS TO THE EXISTING KNOW-HOW 

  

	6.1	CDT hereby grants to Covion an exclusive (save for those non-exclusive licences granted to Dow and Sumitomo referred to in Clauses 2.1.4 and 2.2.2) right to use the Existing
Know-How to exploit Relevant Materials, formulations containing Relevant Materials and the uses of Relevant Materials and such formulations (including, without limitation, processes for the manufacture of any of the foregoing) in any manner in the
Territory during the term of this Agreement. 

  

	6.2	CDT and Covion shall be obliged to work together to effect a transfer of the Existing Know-How within six months from the Effective Date and in that context shall agree what is to
be provided in written form and what can be provided in oral form. In the event that the transfer is not completed by such date neither party shall be under any liability to the other in respect of such failure provided both parties have used their
reasonable endeavours to meet such deadline. 

  

 16 

	7.	LICENCE/RIGHTS TO FUTURE PATENTS AND FUTURE KNOW-HOW IN THE FIELD 

  

	7.1	CDT hereby grants to Covion an exclusive licence under the Future Patents to exploit in any manner within the Field in the Territory during the term of this Agreement:

  

	 	7.1.1	all claims relating to Relevant Materials and all claims to formulations containing Relevant Materials (including, without limitation, claims to processes for the manufacture of any
of the foregoing); and 

  

	 	7.1.2	all claims (if any) to organic semiconductors generally (as distinct from specific classes or types of organic semiconductors) and all claims (if any) to formulations containing
organic semiconductors generally (as distinct from specific classes or types of organic semiconductors) (including, without limitation, claims to processes for the manufacture of any of the foregoing), 

  
 but not (in relation to any or all of the foregoing) any such claim to the
extent that it relates to or concerns the design, development or fabrication of Devices. 
  

	7.2	CDT hereby grants to Covion a non-exclusive licence under the Future Patents to exploit in any manner within the Field in the Territory during the term of this Agreement any claims
under the Future Patents not licensed to Covion pursuant to Clause 7.1 but which make reference to any Relevant Materials and/or formulations containing Relevant Materials which are the subject of the licence referred to in Clause 7.1 PROVIDED
ALWAYS THAT where any such claim relates to or concerns the design, development or fabrication of Devices this licence shall only apply to such claim where such claim (as finally granted) is to an already known (at the date the relevant patent
application is filed) Device comprising a new Relevant Material and/or new formulation containing a Relevant Material (i.e. where the only inventive part of the claim is the presence of the new Relevant Material and/or new formulation containing a
Relevant Material). 

  

	7.3	CDT hereby grants to Covion an exclusive (save for the non-exclusive licence granted to Dow referred to in Clause 2.1.4) right to use the Future Know-How to exploit Relevant
Materials, formulations containing Relevant Materials and the uses of Relevant Materials and such formulations (including, without limitation, processes for the manufacture of any of the foregoing) in any manner within the Field in the Territory
during the term of this Agreement. CDT and Covion shall be obliged to work together to effect a transfer of any relevant Future Know-How in a timely manner (and in any event such transfer shall be completed within six months from the termination or
expiry of the Contract Research Agreement) and 

  

 17 

 in that context shall agree what is to be provided in written form and what can be provided in oral form.
In the event that the transfer is not completed by such date neither party shall be under any liability to the other in respect of such failure provided both parties have used their reasonable endeavours to meet such deadline. 
  

	7.4	Where the Future Patents referred to in Clause 7.1 and/or Clause 7.2 are not solely owned by CDT or are owned by third parties but CDT has relevant rights thereunder which enable
them to license/sub-license Covion in the manner specified in Clause 7.1 and/or Clause 7.2 then, where CDT has to pay royalties or any other form of monetary consideration to a relevant third party for those rights and such royalties or other
consideration are significant in the context of the royalties payable by Covion to CDT under Clause 11, the parties shall be under an obligation to discuss and seek to agree in good faith negotiations, an equitable basis for the allocation between
CDT and Covion of such loyalties or other consideration. If no agreement can be reached within a reasonable period of time then those Future Patents to which such discussions relate shall not form part of the Future Patents licensed/sub-licensed to
Covion in accordance with Clause 7.1 and/or Clause 7.2. 

  

	7.5	In respect of any claims which are the subject of the licences referred to in Clause 7.1 and/or Clause 7.2, CDT hereby undertakes not to assert any such claims against any customer
of Covion or any Covion Licensee or any third party purchasing a product containing any organic semiconductors from such customer where such customer has purchased the organic semiconductors in question (or a formulation containing such organic
semiconductors) from Covion or any Covion Licensee for use within the Field. In respect of any claims that relate to or concern the design, development or fabrication of Devices which are not licensed to Covion pursuant to Clause 7.2, CDT hereby
undertakes not to assert any such claims against any customer of Covion or any Covion Licensee or any third party purchasing a product containing any organic semiconductors from such customer where such customer has purchased the organic
semiconductors in question (or a formulation containing such organic semiconductors) from Covion or any Covion Licensee for use within the Field, provided that such customer has obtained an appropriate licence from CDT or it is manufacturing Devices
otherwise than for sale or other commercial exploitation. 

  

	8.	OTHER LICENCE/RIGHTS TO FUTURE PATENTS AND FUTURE KNOW-HOW 

  

	8.1	CDT hereby grants to Covion an exclusive licence under the Future Patents to exploit in any manner outside the Field in the Territory during the term of this Agreement:

  

	 	8.1.1	all claims relating to Relevant Materials and all claims to formulations containing Relevant Materials (including, without limitation, claims to processes for the manufacture of any
of the foregoing); and 

  

 18 

	 	8.1.2	all claims (if any) to organic semiconductors generally (as distinct from specific classes or types of organic semiconductors) and all claims (if any) to formulations containing
organic semiconductors generally (as distinct from specific classes or types of organic semiconductors) (including, without limitation, claims to processes for the manufacture of any of the foregoing), 

  
 but not (in relation to any or all of the foregoing) any such claim to the
extent that it relates to or concerns the design, development or fabrication of Devices. 
  

	8.2	CDT hereby grants to Covion a non-exclusive licence under the Future Patents to exploit in any manner outside the Field in the Territory during the term of this Agreement any claims
under the Future Patents not licensed to Covion pursuant to Clause 8.1 but which make reference to any Relevant Materials and/or formulations containing Relevant Materials which are the subject of the licence referred to in Clause 8.1 PROVIDED
ALWAYS THAT where any such claim relates to or concerns the design, development or fabrication of Devices this licence shall only apply to such claim where such claim (as finally granted) is to an already known (at the date the relevant patent
application is filed) Device comprising a new Relevant Material and/or new formulation containing a Relevant Material (i.e. where the only inventive part of the claim is the presence of the new Relevant Material and/or new formulation containing a
Relevant Material). 

  

	8.3	CDT hereby grants to Covion an exclusive (save for the non-exclusive licence granted to Dow referred to in Clause 2.1.4) right to use the Future Know-How to exploit Relevant
Materials, formulations containing Relevant Materials and the uses of Relevant Materials and such formulations (including, without limitation, processes for the manufacture of any of the foregoing) in any manner outside the Field in the Territory
during the term of this Agreement. CDT and Covion shall be obliged to work together to effect a transfer of any relevant Future Know-How in a timely manner (and in any event such transfer shall be completed within six months from the termination or
expiry of the Contract Research Agreement) and in that context shall agree what is to be provided in written form and what can be provided in oral form In the event that the transfer is not completed by such date neither party shall be under any
liability to the other in respect of such failure provided both parties have used their reasonable endeavours to meet such deadline. 

  

 19 

	8.4	Where the Future Patents referred to in Clause 8.1 and/or Clause 8.2 are not solely owned by CDT or are owned by third parties but CDT has relevant rights thereunder which enable
them to license/sub-license Covion in the manner specified in Clause 8.1 and/or Clause 8.2 then, where CDT has to pay royalties or any other form of monetary consideration to a relevant third party for those rights and such royalties or other
consideration are significant in the context of the royalties payable by Covion to CDT under Clause 11, the parties shall be under an obligation to discuss and seek to agree in good faith negotiations, an equitable basis for the allocation between
CDT and Covion of such royalties or other consideration. If no agreement can be reached within a reasonable period of time then those Future Patents to which such discussions relate shall not form part of the Future Patents licensed/sub-licensed to
Covion in accordance with Clause 8.1 and/or Clause 8.2. 

  

	8.5	In respect of any claims which are the subject of the licences referred to in Clause 8.1 and/or Clause 8.2, CDT hereby undertakes not to assert any such claims against any customer
of Covion or any Covion Licensee or any third party purchasing a product containing any organic semiconductors from such customer where such customer has purchased the organic semiconductors in question (or a formulation containing such organic
semiconductors) from Covion or any Covion Licensee for use outside the Field. In respect of any claims that relate to or concern the design, development or fabrication of Devices which are not licensed to Covion pursuant to Clause 8.2, CDT hereby
undertakes not to assert any such claims against any customer of Covion or any Covion Licensee or any third party purchasing a product containing any organic semiconductors from such customer where such customer has purchased the organic
semiconductors in question (or a formulation containing such organic semiconductors) from Covion or any Covion Licensee for use outside the Field, provided that such customer has obtained an appropriate licence from CDT or it is manufacturing
Devices otherwise than for sale or other commercial exploitation. 

  

	8.6	The exclusive licence and right granted to Covion pursuant to Clauses 8.1 and 8.3 shall become a sole licence and right in respect of a particular organic semiconductor or
formulation containing such organic semiconductor if Covion does not within six months of a bona fide customer request received either directly or via CDT commence scale-up to manufacture in respect of the particular organic semiconductor or
formulation containing such organic semiconductor. In such circumstances CDT may engage a toll manufacturer to produce the relevant product. 

  

	9.	USE OF KNOW-HOW 

  

	9.1	CDT warrants that all Existing Know-How disclosed or to be disclosed to Covion hereunder is or will be, to the best of CDT’s knowledge and belief, accurate

  

 20 

 (provided always that CDT will promptly correct any significant errors in the Existing Know-How
subsequently discovered by CDT) but subject thereto CDT shall be under no further liability to Covion in respect of the Existing Know-How or of the exploitation thereof (including, without limitation, the exploitation of Covion Products).

  

	9.2	CDT hereby undertakes to warrant at the time of such disclosure of any such Future Know-How that such Future Know-How then disclosed to Covion hereunder is, to the best of
CDT’s knowledge and belief, accurate (provided always that CDT will promptly correct any significant errors in the Future Know-How subsequently discovered by CDT) but subject thereto CDT shall be under no further liability to Covion in respect
of the Future Know-How or of the exploitation thereof (including, without limitation, the exploitation of Covion Products). 

  

	9.3	Covion shall be exclusively responsible for all Covion Products manufactured sold, used or supplied by Covion or any Covion Licensee and accordingly Covion shall indemnify and keep
indemnified CDT (and shall procure that any Covion Licensee indemnifies and keeps indemnified CDT) in respect of all costs damages and expenses incurred as a result of any claims by third parties in tort or howsoever otherwise including, without
limitation, any relevant legislation or regulation against CDT arising in any way out of the use of any of the Patents and/or Know-How by or for Covion or by or for any Covion licensee. 

  

	10.	SUB-LICENSING AND ASSIGNMENT 

  

	10.1	Covion may grant sub-licences within the scope of its own rights granted under Clauses 3 to 8 to any Covion Licensee but shall not, subject to Clause 10.2, otherwise sub-license,
assign, charge or transfer to any party any of its rights granted hereunder without first obtaining the express written consent of CDT. However the rights granted pursuant to Clause 4 may only be exploited by either Covion or one Covion licensee and
not by more than one of such entities. Covion’s ability to sub-license the rights granted pursuant to Clause 4 shall be restricted accordingly. CDT shall be promptly notified by Covion of any such sub-licence. 

  

	10.2	Sub-licences granted by Covion and/or any Covion Licensee to toll manufacturers (excluding those based in the Peoples Republic of China) employed by such entity to manufacture
Covion Products for such entity shall not require the consent of CDT. 

  

	10.3	If at any time Covion ceases to be an Affiliate of Avecia any sub-licence previously granted by Covion pursuant to clause 10.1 shall automatically terminate at that time in respect
of any business entity which at the relevant time is no longer an Affiliate of Covion or Relevant Joint Venture of any Covion Group Company. 

  

 21 

	10.4	If a sub-licence is granted to a Relevant Joint Venture of (a) any Covion Group Company or (b) any Avecia Group Company and that Relevant Joint Venture has as a shareholder holding
at least 5% of the equity share capital of any Dow Group Company, then the licence to exploit in any manner the rights which are the subject of the sub-licence to that Relevant Joint Venture shall become permanently non-exclusive as between Covion
and CDT with respect to the field/fields in which that Relevant Joint Venture is exploiting such licence and rights. 

  

	10.5	All sub-licences granted under this Agreement shall, with only the necessary changes having been made, contain the same obligations and limitations as are contained in this
Agreement. Covion shall ensure and guarantee to CDT that its sub-licensees will comply with those obligations (including, but without being limited to, the payment of all sums due to CDT in respect of Covion Products exploited by them) as if such
sub-licensees were party to this Agreement. Any act or omission of a Covion Licensee or a toll manufacturer pursuant to any sub-licence shall be deemed to be an act or omission of Covion pursuant to this Agreement. 

  

	10.6	On termination of this Agreement for any reason all sub-licences shall automatically terminate unless CDT, in its absolute discretion, agrees by way of written notice to treat any
sub-licence as a continuing licence subject to the whole or part of the terms of such continuing licence being agreed. 

  

	10.7	A party may not assign or transfer all or any part of its rights or obligations under this Agreement without the prior written consent of the other party (such consent not to be
unreasonably withheld or delayed) save that both the benefit and the burden of all its provisions may be transferred on notice to the other party to the following: 

  

	 	10.7.1	any company which is a subsidiary, fellow subsidiary or holding company of the party concerned (each a “Qualifying Company”) but, by accepting such a transfer and
as a condition thereof, the transferee shall be deemed to agree with the parties to this Agreement to re-transfer both the benefit and the burden of all its provisions to the party concerned or another of its Qualifying Companies before itself
ceasing to be a Qualifying Company in relation to such party; or 

  

	 	10.7.2	a purchaser of all or substantially all of the assets of the business to which this Agreement relates, 

  

 22 

 and the parties shall execute such documents as may be appropriate to effect such transfers. However if
the benefit and burden of the provisions of this Agreement is transferred by Covion or any successor in title thereof to any Dow Group Company or any Sumitomo Group Company then all licences and rights granted to Covion pursuant to this Agreement
shall become non-exclusive. 
  

	10.8	The Patents and Know-How cannot be assigned or transferred by CDT or any successor in title thereof other than as part of a transfer of the rights and obligations of CDT or any
successor in title thereof under this Agreement. Except with the prior consent of Covion or any successor in title thereof (which consent shall not be unreasonably withheld or delayed) any transfer of the rights and obligations of CDT or any
successor in title thereof under this Agreement must be accompanied by an assignment or transfer of the Patents and Know-How. 

  

	10.9	Save as provided by clause 10.7.1, change of control of either party shall have no effect on this Agreement save that if the acquiring party of Covion or any successor in title
thereof is any Dow Group Company or any Sumitomo Group Company then all licences and rights granted to Covion pursuant to this Agreement shall become nonexclusive. 

  

	11.	ROYALTIES 

  

	11.1	Covion shall, in respect of the licences and rights granted to Covion pursuant to Clauses 3 to 8, pay to CDT a royalty (excluding VAT or other sales tax if applicable) of [**] of
the Net Sales Value of all Covion Products sold during the relevant periods defined in accordance with Clause 11.2. 

  

	11.2	The royalty referred to in Clause 11.1 shall be payable on all Covion Products for a period of ten years from the Effective Date. This period may be extended depending on the Covion
Products involved as follows: 

  

	 	11.2.1	if the sale or any other aspect of the exploitation of a Covion OLEM Product falls within any of the then still valid claims in a patent or patent application which is owned by
Covion for an invention covered by Clause 7.5 of the Contract Research Agreement (or in the case of a patentable process invention would have fallen within such claims had Covion not decided to keep such invention secret rather than patent it as
contemplated by and in accordance with Clause 7.5 of the Contract Research Agreement) and which has as an inventor a person whose salary was actually paid by CDT at the time of such invention, then the royalty on Covion OLEM Products will continue
to be paid for ten years after the date of filing of the last such patent application to be made (or if kept secret ten years after the date on which the decision not to patent the patentable process invention was notified in writing to CDT) or
until the expiry of the last of the Patents under which claims are licensed to Covion pursuant to this Agreement, whichever is the earlier; 

  

 23 

  

	 	11.2.2	if the sale or any other aspect of the exploitation of a Covion OSC Product falls within any of the then still valid claims in: 

  

	 	(a)	a patent or patent application which is owned by Covion for an invention covered by Clause 7.5 of the Contract Research Agreement (or in the case of a patentable process invention
would have fallen within such claims had Covion not decided to keep such invention secret rather than patent it as contemplated by and in accordance with the Clause 7.5 of the Contract Research Agreement) and which has as an inventor a person whose
salary was actually paid by CDT at the time of such invention; or 

  

	 	(b)	a Future Patent licensed to Covion in accordance with this Agreement, 

  
 then the royalty on such Covion OSC Product will be paid for ten years after the date of filing of the last such patent application (or if kept secret
ten years after the date on which the decision not to patent the patentable process invention was notified to CDT) which has claims that such Covion OSC Product falls within; or if longer for five years after the first commercial sale of such Covion
OSC Product or such shorter period as the relevant patent or Future Patent remains in force (or the relevant patent would have remained in force if the patent application had been filed on the date on which the decision was made to keep it secret).

  

	11.3	For the avoidance of doubt no royalties shall be payable on sales of Covion Products by Covion or any Covion Licensee to any CDT Group Company or any other company in which CDT owns
at least 25% of the equity share capital. Also for the avoidance of doubt royalties on any Covion Products manufactured by any toll manufacturer as contemplated by clause 10.2 shall be payable on the subsequent sale of those products by Covion or
any Covion Licensee and not on the original sale by the toll manufacturer to them. 

  

	11.4	No royalties shall be due to CDT in respect of any Covion Products used by Covion or any Covion Licensee for the further development of Covion Products by Covion or any Covion
Licensee or for quality control procedures in the manufacture or sale of Covion Products or disposed of free of charge for the purposes of promoting the sale of Covion Products. 

  

	11.5	In this Agreement the expression “sold” or any cognate expression shall be deemed to include any type of supply for value. 

  

 24 

	11.6	Covion shall, in respect of the licences and rights granted to Covion pursuant to Clauses 3 to 8, also pay to CDT a royalty (excluding VAT or other sales tax if applicable) of [**]
of the Royalty Income obtained by Covion or any Covion Licensee for a period of ten years after the date of filing of the last relevant patent application (or if kept secret ten years after the date on which the decision not to patent the patentable
process invention was notified to CDT) where such Royalty Income is derived from sales by a third party licensee in the Field. Where such Royalty Income is derived from sales by a third party licensee outside the Field then, if longer than the
period specified above, such royalty on Royalty Income which is derived from sales by a third party licensee outside the Field shall be paid for five years after the first receipt of any such Royalty Income or such shorter period as the relevant
patent remains in force (or would have remained in force if the patent application had been filed on the date on which the decision was made to keep it secret). 

  

	12.	ACCOUNTING AND PAYMENT 

  

	12.1	Royalties shall be payable yearly in arrears sixty (60) days after the end of the last day of each calendar year during the term of this Agreement in which royalties accrue.

  

	12.2	Covion shall and shall procure that any Covion Licensee shall keep at its usual place of business records of account sufficient to enable accurate calculations of royalties due to
CDT and shall produce a statement of those royalties no later than sixty (60) days after the end of each calendar year during the term of this Agreement. If there is a dispute between the parties about the amount of royalties payable, the parties
shall select an independent accountant to be agreed between them, or in default of agreement to be appointed by the President for the time being of the Institute of Chartered Accountants in England and Wales, to inspect the records of Covion and/or
any Covion Licensee on reasonable notice and during normal business hours to verify Covion’s statements and royalty payments due pursuant to this Agreement. If such inspection reveals that any statement or payment shall not have been rendered
or made in accordance with the terms of this Agreement, or that any statement rendered or payment made by Covion was inaccurate by more than five per cent (5%) then Covion shall pay the cost of such inspection without prejudice to any other remedies
or claims of CDT. Such accountant shall not disclose to CDT any information other than information relating to royalties owed by Covion pursuant to this Agreement. CDT shall maintain in confidence and shall oblige the independent accountant to
maintain in confidence all information received pursuant to this sub-clause. The decision of the independent accountant as to the amount of royalty payment to be made shall, in the absence of manifest error, be final and binding upon the parties.

  

 25 

	12.3	All royalties shall be calculated in the currency in which Covion keeps its accounts and shall be paid to CDT in euros in London to the credit of a bank account to be designated in
writing by CDT, the rate of conversion being the relevant buying rate of HSBC Bank plc at close of business on the last business day of the before the day payment is due. 

  

	12.4	All sums shall be paid in full without deductions or set-off, except only for such taxes, or other levies or duties as Covion is legally bound to withhold. Covion shall assist CDT
without charge to recover (under the provisions of double tax conventions or other lawful manner) any tax so withheld. If VAT is payable on any of the royalties then Covion shall pay VAT pursuant to a VAT invoice to be submitted by CDT.

  

	12.5	CDT agrees that if requested by Covion it shall at Covion’s cost (including the payment of stamp duty) record the licence of the Patents licensed to Covion pursuant to this
Agreement on all the appropriate patent registers. 

  

	13.	COVION PRODUCTS 

  
 As further consideration to CDT and only where such Covion Products are available to any third party, Covion undertakes to provide (and/or procure that any relevant Covion Licensee provides) each CDT Group Company and
up to three business entities in which CDT, directly or indirectly, owns at least 25% of the outstanding voting securities or capital stock of such business entities (or any other comparable equity or ownership interest with respect to any business
entity other than a corporation) with Covion Products at the best price at which Covion or any Covion Licensee makes those Covion Products available to any third party for a use similar to the use for which CDT requires such Covion Products (i.e.
equivalent field of use for the same material or formulation). This undertaking applies irrespective of the volume or other terms and conditions which the third party may have agreed to in order to obtain such price from Covion or Covion Licensee.

  

	14.	CONFIDENTIALITY 

  

	14.1	Without the prior written consent of the other party (which shall not be unreasonably withheld or delayed), neither party shall disclose to any third party the existence of this
Agreement, any part of the contents or terms and conditions of this Agreement or any other facts in respect of this Agreement. 

  

	14.2	In consideration of the Disclosing Party disclosing or otherwise making available any Confidential Information to the Receiving Party, the Receiving Party hereby undertakes:

  

	 	14.2.1	to maintain the confidentiality of the Confidential Information and not to disclose it directly or indirectly to any third party, whether an affiliated company, organisation,
individual or otherwise, save as permitted by Clauses 14.3 to 14.5; and 

  

 26 

	 	14.2.2	to take reasonable and appropriate measures to secure the confidentiality attaching to the Confidential Information of the Disclosing Party and safeguard it against theft, loss or
negligent disclosure to others, including but not limited to the same measures as the Receiving Party takes to protect its own confidential information. 

  

	14.3	The Receiving Party may disclose Confidential Information to: 

  

	 	14.3.1	any of its Affiliates provided that the Receiving Party shall procure that prior to such disclosure each Affiliate to which Confidential Information is to be disclosed is made aware
of the obligations contained in this Agreement and agrees to be subject to confidentiality obligations no less onerous than those contained in this Agreement; any breaches of the obligations of confidentiality contained in this agreement by such
Affiliates shall be treated as a breach of such obligations by the Receiving Party; and 

  

	 	14.3.2	its directors and employees and/or other personnel (and to the directors and employees and/or other personnel of the Affiliates to whom disclosure may be made in accordance with
Clause 14.3.1) who need to know the Confidential Information in order to fulfil the Purpose, provided that the Receiving Party shall procure that prior to such disclosure each of those directors and employees and/or other personnel to whom
Confidential Information is to be disclosed is made aware of the obligations of confidentiality, non-analysis and non-use herein contained and any breaches of the obligations of confidentiality, non-analysis and non-use contained in this Agreement
by such directors, employees and/or other personnel (and directors and employees and/or other personnel of such Affiliates) shall be treated as a breach of such obligations by the Receiving Party. 

  
 Any reference to the Receiving Party in Clause 14.6 where such Receiving
Party is Covion shall be deemed to include reference to its Affiliates to whom Confidential Information of CDT has been disclosed pursuant to this Clause 14.3. Any reference to the Receiving Party in Clause 14.6 where such Receiving Party is CDT
shall be deemed to include reference to its Affiliates to whom Confidential Information of Covion has been disclosed pursuant to this Clause 14.3 
  

 27 

	14.4	Nothing in this Clause 5 shall preclude disclosure of any Confidential Information required by any court entitled by law to disclosure of the same, or which is required by law to be
disclosed, provided that the Receiving Party promptly notifies the Disclosing Party when such requirement to disclose has arisen, to enable the Disclosing Party to seek an appropriate protective order and to make known to the said court the
proprietary nature of the Confidential Information and to make any applicable claim of confidentiality in respect thereof. The Receiving Party agrees to co-operate in any appropriate action which the Disclosing Party may decide to take. If the
Receiving Party is required to make a disclosure it shall only make a disclosure to the extent to which it is obliged. The parties agree that any submission or presentation to any competition law authority in relation to this Agreement shall be made
jointly, but nothing in this Clause 14 shall preclude the making of an appropriate submission or presentation to any competition law authority in response to a legal requirement imposed by a competition law authority provided that the party in
receipt of such a requirement promptly notifies the other party and consults with the other party as to the content of such submission or presentation. 

  

	14.5	Where Covion is the Receiving Party then it shall be entitled to disclose the Know-How to third parties where this is necessary in order to develop, market and/or sell Covion
Products, provided that in deciding whether to disclose such Know-How Covion uses the same criteria as it would if the Know-How belonged to Covion. 

  

	14.6	The provisions of this Clause 14 shall not apply to any information comprising Confidential Information which the Receiving Party can demonstrate to the reasonable satisfaction of
the Disclosing Party: 

  

	 	14.6.1	was already in the possession of the Receiving Party and at the Receiving Party’s free use and disposal or in the public domain prior to its disclosure by the Disclosing Party
hereunder; or 

  

	 	14.6.2	is legally acquired by the Receiving Party at any time from a third party having good title thereto and the unrestricted right to disclose the same; or 

  

	 	14.6.3	comes into the public domain, otherwise than through the fault of the Receiving Party; or 

  

	 	14.6.4	is independently generated by the Receiving Party without any recourse or reference to any Confidential Information disclosed by the Disclosing Party. 

  

 28 

	14.7	The obligations of the Receiving Party set out in this Clause 14 shall is respect of the Confidential Information of the Disclosing Party survive for a period of five years from the
termination of this Agreement. 

  

	15.	PERFORMANCE 

  
 During the continuance of this Agreement Covion shall: 
  

	15.1	use its reasonable commercial efforts to promote the sale of the Covion Products in the Territory; as widely as its resources reasonably permit. 

  

	15.2	not act as agent of CDT and specifically not give any indication that it is acting otherwise than as principal and in advertising or selling Covion Products not make any
representation or give any warranty on behalf of CDT. 

  

	16.	THIRD PARTY INFRINGEMENTS 

  

	16.1	Covion shall promptly inform CDT by way of notice in writing (giving as much by way of particulars as Covion has available to it to enable the same to be properly evaluated) of any
suspected infringement of the claims licensed to Covion under the Patents pursuant to Clauses 3, 7 and/or 8 of this Agreement by any third party which may come to Covion’s notice (or which Covion has reasonable grounds for believing is taking
place) at any time during the period referred in Clause 11.2 during which Covion is paying royalties to CDT under this Agreement and in respect of which Covion requires CDT to take action (the date such notice is served on CDT being hereinafter
referred to as the “Notification Date”). CDT shall be obliged to respond to any such notice within thirty (30) days of the date of service informing Covion as to whether it will take any action in respect of the suspected
infringement. 

  

	16.2	If CDT elects to take any action in respect of any such suspected infringement, it will do so at its own expense and shall keep Covion informed as to the action being taken or to be
taken and the progress thereof. CDT undertakes to pursue any such action diligently as CDT’s resources reasonably permit and in accordance with good industrial and commercial practice. 

  

	16.3	If CDT elects not to take any action or does not take any action within a reasonable period of time, then Covion shall be entitled at its own expense to take such action (whether by
way of court proceedings or otherwise) as it deems appropriate in respect of this suspected infringement and will keep CDT informed as to the action being taken or to be taken and the progress thereof; for this purpose CDT will at its own expense
provide such in-house assistance and information as Covion may reasonably require and shall permit Covion to use the name of CDT in any such action taken by Covion provided Covion pays due 

  

 29 

 regard to CDT’s reasonable directions as to the conduct of action. In such circumstances if Covion
takes action in respect of a suspected infringement where the sale or any other aspect of the exploitation of a Covion OSC Product falls within the claims involved in the suspected infringement and but for such claims Covion would not be obliged to
pay any royalty to CDT in respect of such Covion OSC Product, then the provisions of Clause 16.4 shall not apply to such infringement. If Covion does not take any action then save in respect of any such suspected infringement covered by the
provisions of Clause 16.4 no further action is necessary by either party in respect of the said infringement. 
  

	16.4	Where the sale or any other aspect of the exploitation of a Covion OSC Product falls within the claims involved in any such suspected infringement and but for such claims Covion
would not be obliged to pay any royalty to CDT in respect of such Covion OSC Product then no further royalty shall be due or payable with effect from the Notification Date in respect of the said claims unless or until: 

  

	 	16.4.1	CDT institutes legal proceedings for infringement against the third party; or 

  

	 	16.4.2	CDT provides Covion with the opinion of Queens Counsel obtained pursuant to the provisions of Clause 16.5 that there is insufficient evidence for an actionable case for infringement
proceedings against the third party with a realistic prospect of a favourable outcome, 

  
 following which Covion shall account to CDT on the next date on which a royalty is to be paid for all royalties in respect of the Covion OSC Products
falling within such claims which have not been paid since the Notification Date. In such circumstances if CDT then fails to pursue diligently any legal proceedings for infringement once instituted or the result of the legal proceedings is that the
particular claims are revoked due to invalidity or CDT notifies Covion that it does not intend to take legal proceedings for infringement where CDT has not obtained the opinion referred to in Clause 16.4.2 above, then in each case, the licence
provided for in Clause 3 or 8 (as the case may be) shall in respect of the particular claims, solely as regards the relevant Covion OSC Product(s), become royalty-free in relation to that part of the Territory covered by the specific patent
containing the particular claims involved in the suspected infringement with effect from the Notification Date and any relevant royalties paid by Covion relating to a period on or after the Notification Date shall be reimbursed to Covion by CDT
within 90 days. 
  

	16.5	Where the sale or any other aspect of the exploitation of a Covion OSC Product falls within the claims involved in the suspected infringement and but for such claims Covion would
not be obliged to pay any royalty to CDT in respect of such Covion OSC Product then if CDT is not satisfied that there is sufficient evidence 

  

 30 

 for an actionable case for infringement proceedings against the third party, it shall be entitled to
refer the matter to a Queens Counsel reasonably acceptable to both parties acting reasonably, with the costs of referral being shared by the parties equally. Both parties shall at their own respective costs diligently provide such Queens Counsel
with all necessary assistance and evidence regarding the matter in order to allow the Queens Counsel to provide a properly reasoned and informed opinion. Such opinion shall state whether there is sufficient evidence for an actionable case for
infringement proceedings against the third party with a realistic prospect of a favourable outcome. 
  

	16.6	Any damages, fees, costs, royalties or other monies recovered from any third party by either party as a result of any action taken by that party in accordance with this clause 16
shall be retained by that party. 

  

	16.7	If Covion takes infringement proceedings in accordance with Clause 16.3 then Covion shall be entitled to deduct from the royalties payable to CDT pursuant to this Agreement 50% of
their reasonable unrecovered costs in respect of the infringement proceedings (for these purposes any damages, fees, costs, royalties or other monies recovered from any third party involved shall be deemed deducted from any reasonable unrecovered
costs) up to a maximum of one half of the royalties payable to CDT under this Agreement after the Notification Date for such infringement. Where the infringement proceedings commenced by Covion in accordance with Clause 16.3 involve claims where the
sale or any other aspect of the exploitation of a Covion OSC Product falls within such claims and but for such claims Covion would not be obliged to pay any royalty to CDT in respect of such Covion OSC Product, then Covion’s right of recovery
pursuant to this Clause 16.7 shall be limited to one half of the royalties payable to CDT under this Agreement in respect of the Covion OSC Products concerned after the Notification Date for such infringement. 

  

	16.8	Any deduction/right of recovery referred to in Clause 16.7 shall only commence with the first royalty payment date after the infringement proceedings have finished and Covion’s
aggregate unrecovered costs have been ascertained. Such deduction shall then be made from such royalty payment and each subsequent royalty payment until Covion have recovered 50% of their reasonable unrecovered costs in respect of the infringement
proceedings (taking into account any recoveries referred to in Clause 16.7) provided always that Covion shall not be able to deduct more than 50% of the royalty payment due to CDT on any particular royalty payment date. In the event that Covion have
not recovered 50% of their reasonable unrecovered costs in respect of the infringement proceedings (taking into account any recoveries referred to in Clause 16.7) by the date on which the last royalty payment is made to CDT under this Agreement
(“the Final Royalty Payment Date”), CDT shall pay the balance of any such costs not yet paid to Covion within 60 days of the Final Royalty Payment Date. 

  

 31 

	17.	MAINTENANCE OF PATENTS 

  
 CDT shall during that part of the term of this Agreement during which Covion is paying royalties to CDT as contemplated hereunder keep in force at its
expense the Patents under which claims are licensed to Covion pursuant to Clauses 3, 7 and 8 of this Agreement. However Covion and CDT shall discuss from time to time the scope of the Patents under which claims are licensed to Covion pursuant to
Clauses 3, 7 and 8 of this Agreement in conjunction with the types of organic semiconductors being developed and the Covion Products being sold in order to allow CDT to actively manage its patent portfolio and the costs relating thereto in a cost
effective and sensible manner, taking into account all relevant circumstances. Covion shall be notified by CDT in writing if CDT decides to abandon or surrender any of the Patents which contain any claims licensed to Covion in accordance with
Clauses 3,7 and 8 of this Agreement and any such Patents shall first be offered to Covion. CDT may without any recourse abandon, surrender or otherwise allow such Patents to lapse unless Covion notifies CDT within 2 (two) months of notification that
Covion wishes to take ownership of any such Patents whereupon Covion shall be responsible for preparing the assignment and will bear all patent office costs and all taxes associated with transferring and registering assignment of such Patent from
CDT to Covion. Where such Patent contains claims where the sale or any other aspect of the exploitation of a Covion OSC Product falls within such claims and but for such claims Covion would not be obliged to pay any royalty to CDT in respect of such
Covion OSC Product then no further royalty in respect of the Covion OSC Product(s) in question shall be payable in respect of the claims under such Patent from the date on which the assignment is executed. 
  

	18.	TERM AND TERMINATION 

  

	18.1	This Agreement shall come into effect on the Effective Date and unless terminated earlier in accordance with the following provisions of this clause shall remain in force until the
later of the date when the last of the Patents licensed to Covion pursuant to Clauses 3 to 8 of this Agreement expires, lapses, becomes abandoned or is revoked following a final decision from which no further appeal is possible and the date when the
last of the Know-How comes into the public domain. On the date on which the last of the Patents licensed to Covion pursuant to Clauses 3 to 8 of this Agreement expires, lapses, becomes abandoned or is revoked following a final decision from which no
further appeal is possible, the licences granted pursuant to Clauses 6.1, 7.3 and 8.3 shall become sole licences. For the avoidance of doubt once a particular piece of Know-How comes into the public domain (other than through the fault of CDT) the
licences granted pursuant 

  

 32 

 to Clauses 6.1, 7.3 and 8.3 shall become non-exclusive licences in respect of that particular piece of
Know-How. Also for the avoidance of doubt any CDT Group Company shall be able to exploit any claim exclusively licensed to Covion pursuant to this Agreement in a patent comprised in the Patents once that patent expires, lapses, is abandoned or is
revoked following a final decision from which no further appeal is possible unless Covion is still paying royalties on Covion OLEM Products in which case no CDT Group Company shall be able to exploit any such claim in the Field until Covion ceases
to pay such royalties. 
  

	18.2	In the event that either party is in material breach of the terms of this Agreement and, in the case of a breach capable of being remedied, fails to remedy that breach within thirty
days of receiving written notice specifying that breach and requiring the same to be remedied, the other party may terminate this Agreement forthwith by notice in writing. 

  

	18.3	In the event that: 

  

	 	18.3.1	Covion has a liquidator, receiver, administrator or administrative receiver appointed in respect of the whole or any material part of its undertaking or assets or enters into any
arrangement or composition with its creditors or calls a meeting of its creditors or is the subject of an order made or resolution passed for its winding up, whether voluntarily or compulsorily (except for the purposes of a bona fide reconstruction
or amalgamation) or has an event analogous to any of those referred to above happen to it under the laws of any jurisdiction in which it is constituted or registered; and 

  

	 	18.3.2	whilst such an event referred to in Clause 18.3.1 is continuing (but not after it ceases) Covion fails to pay within fourteen days of demand any sum due and payable under this
Agreement, 

  
 then CDT may terminate this
Agreement forthwith by notice in writing to Covion. 
  

	18.4	Save as provided in Clause 4.4, CDT may terminate this Agreement forthwith if Covion has after the date of this Agreement taken directly or indirectly any steps to seek to establish
the invalidity of, or otherwise oppose, any of the Patents licensed to Covion pursuant to Clauses 3 to 8 of this Agreement or to procure or assist any third party to do so provided that this shall not apply to any such steps taken incidentally or
inadvertently or which Covion can show were otherwise not taken with the intention of so assisting the third party. 

  

	18.5	Covion shall procure that the provisions of clauses 18.1 to 18.4 shall apply, with only the necessary changes having been made, to any sub-licences granted by Covion hereunder, to
the intent that CDT shall have in respect of sub-licensees the same rights as it has in respect of Covion. 

  

 33 

	19.	CONSEQUENCES OF TERMINATION 

  

	19.1	Termination of this Agreement and of any licences granted hereunder shall be without prejudice to the rights of either party which have accrued up to the date of termination
including, without limitation, the rights of CDT to sue for and recover any royalties or other payments then due and to pursue any remedy in respect of any breach by Covion of any of the terms of this Agreement. 

  

	19.2	Covion shall have the right to sell any stocks of Covion Products which have been manufactured but which remain unsold at the date of termination subject to the payment to CDT of
the relevant royalty pursuant to Clause 11 and such sales being made no later than 6 months after such termination. 

  

	19.3	The provisions of Clauses 11 and 12 of this Agreement relating to the payment of royalties and other sums and the rendering and auditing of accounts and other information shall
remain in force as long as may be necessary in order to wind up the outstanding obligations of both parties hereunder. 

  

	19.4	Upon the termination of this Agreement for any reason the provisions of Clauses 1, 11 and 12 (as provided for in Clause 19.3 above), 14, 19, 20 and 22 shall continue in force in
accordance with their respective terms. 

  

	20.	NATURE OF AGREEMENT 

  

	20.1	Each party acknowledges that in entering into this Agreement it places no reliance on any representation or warranty relating to the subject matter of this Agreement save as
expressly set out in this Agreement and each party shall have no liability in respect of any representation, warranty or promise made prior to the date of this Agreement unless it was made fraudulently. This Agreement represents the entire agreement
between the parties in relation to the subject matter of this Agreement and supersedes any previous agreement or undertaking between the parties and may not be modified except by an instrument in writing and signed by duly authorised representatives
of both parties. 

  

	20.2	Should any provision of this Agreement, be held to be illegal, invalid or unenforceable in any respect by any judicial or other competent authority under the law of any
jurisdiction: 

  

	 	20.2.1	such provision shall, so far as it is illegal, invalid or unenforceable in any jurisdiction, be given no effect by the parties and shall be deemed not to be included in this
Agreement in that jurisdiction; 

  

	 	20.2.2	the other provisions of this Agreement shall be binding on the parties in that jurisdiction as if such provision were not included herein; 

  

 34 

	 	20.2.3	the legality, validity and enforceability of the provision in any other jurisdiction shall not be affected or impaired; and 

  

	 	20.2.4	the parties agree to negotiate in good faith to amend such provision to the extent possible for incorporation herein in such reasonable manner as most closely achieves the intention
of the parties without impairing the parties’ original interests and without rendering such provision invalid or unenforceable. 

  

	20.3	No delay or omission on the part of any party to this Agreement in exercising any right, power or remedy provided by law or under this Agreement shall impair such right, power or
remedy; or operate as a waiver thereof. 

  

	20.4	The single or partial exercise of any right, power or remedy provided by law or under this Agreement shall not preclude any other or further exercise thereof or the exercise of any
other right, power or remedy. 

  

	20.5	The rights, powers and remedies provided in this Agreement are cumulative and not exclusive of any rights, powers and remedies provided by law. 

  

	20.6	Nothing in this Agreement shall be construed so as to constitute either party to be the agent of the other. 

  

	20.7	Nothing in this Agreement and no action taken by the parties pursuant to this Agreement shall constitute a partnership or joint venture of any kind between the parties hereto.

  

	20.8	This Agreement shall be binding on the successors and permitted assigns of the parties. 

  

	20.9	Unless expressly provided in this Agreement, no term of this Agreement is enforceable pursuant to the Contracts (Rights of Third Parties) Act 1999 by any person who is not a party
to it. 

  

	20.10	The parties shall make all reasonable endeavours to reach an amicable settlement of any dispute, controversy or difference that may arise between the parties out of or in relation
to this Agreement. In the event of any dispute, controversy or difference that may arise the parties shall in the first instance promptly refer the matter to the parties’ senior business managers. Should the senior business managers be unable
to resolve the dispute within 20 days of the matter being referred to them then the parties shall then promptly refer the matter to a director of each of the parties. Should the directors be unable to resolve the dispute within 20 days of the matter
being referred to them then the matter shall be finally settled, without right of appeal, in accordance with the Rules of Conciliation and 

  

 35 

 Arbitration of the International Chamber of Commerce by an arbitrator or arbitrators appointed in
accordance with said Rules. Such arbitration shall take place in London, England. The provisions of this clause shall not prejudice the application of Clause 18 and shall also not apply to any breach of clause 14 (Confidentiality) which shall be
subject to the non-exclusive jurisdiction of the English courts and for these purposes Covion appoints Avecia Limited as its agent to accept service. 
  

	20.11	Each party will at all times act in the utmost good faith towards the other in connection with this Agreement and the matters referred to therein. 

  

	20.12	Neither party shall make any announcement with respect to the arrangements contemplated by this Agreement without the written consent of the other as to the form content, and timing
of the announcement (such consent not be unreasonably withheld or delayed). 

  

	20.13	Notwithstanding Clauses 14.1 and 20.12 the parties shall make a joint announcement within 60 days of the signature of this Agreement. The text of such announcement shall be agreed
by the parties and it shall not be made public until such agreement is reached. 

  

	20.14	This Agreement has been duly executed and delivered by CDT and all obligations of CDT therein are legal, valid and binding obligations which are enforceable against CDT in
accordance with their terms. In particular the granting of the licences over the Patents and Know-How does not violate any law, statute, ordinance, regulation, order, judgment or decree of any court or governmental agency applicable to any CDT Group
Company, or violate, or conflict with, any contract, commitment, agreement, understanding or arrangement of any kind to which any CDT Group Company is a party or by which any CDT Group Company is bound. CDT shall ensure and guarantee to Covion that
any CDT Group Company that owns any Patents and/or Know-How will comply with all obligations in this Agreement as if such CDT Group Company were party to this Agreement. Any act or omission of such CDT Group Company shall be deemed to be the act or
omission of CDT pursuant to this Agreement. 

  

	20.15	In respect of any claims under the Existing Patents and/or the Future Patents that relate to or concern the design, development or fabrication of Devices which make reference to any
Relevant Materials or formulations containing Relevant Materials, CDT hereby confirms and undertakes to Covion that all CDT’s Device licensees will have been offered, and will continue to be offered, as part of CDT’s standard offering(s),
licences under the Existing Patents and the Future Patents to all such claims not licensed to Covion under this Agreement. 

  

 36 

	21.	NOTICES 

  

	21.1	All notices and other communications given or made in relation to this Agreement: 

  

	 	21.1.1	shall be in English and in writing; 

  

	 	21.1.2	shall be delivered by hand or sent by express courier (e.g. DHL) or by facsimile; 

  

	 	21.1.3	shall be delivered or sent to the party concerned at the relevant address or facsimile number, shown in clause 21.2 subject to such amendments as may be notified from time to time
in accordance with this clause by the relevant party to the other party by no less than 3 Business Days’ notice; and 

  

	 	21.1.4	shall be deemed to have been duly given or made if addressed in the aforesaid manner: 

  

	 	(i)	if delivered by hand, upon delivery; 

  

	 	(ii)	if posted by express courier, on the date of receipt; and 

  

	 	(iii)	if sent by facsimile, when a complete and legible copy of the communication has been received at the appropriate address; 

  
 provided that if any notice or other communication would otherwise become
effective on a non-Business Day or after 5.00 p.m. on a Business Day, it shall instead be deemed to be given or made at 10.00 a.m. on the next Business Day. 
  

	21.2	The initial details for the purposes of clause 21.1 are: 

  

			
	 Covion:
	  	 Covion Organic Semiconductors GmbH

	 	  	 Industriepark Hoechst, Gebaude G864

	 	  	 D-65926 Frankfurt am Main

	 	  	 Germany

	 	  	 Facsimile No.: +49 69 3054 7570

	 	  	 For the attention of: Managing Director

  

 37 

			
	 with a copy to:
	  	 Avecia Limited

	 	  	 Legal Affairs Department

	 	  	 PO Box No. 42, Hexagon House

	 	  	 Blackley, Manchester

	 	  	 M9 8ZS

	 	  	 England

	 	  	 Facsimile No.: +44 161 721 1886

	 	  	 For the attention of: Company Secretary

		
	 CDT:
	  	 Cambridge Display Technology Limited

	 	  	 Greenwich House, Madingley Rise

	 	  	 Madingley Road, Cambridge

	 	  	 CB3 0HJ

	 	  	 England

	 	  	 Facsimile No.: +44 1223 723503

	 	  	 For the attention of Dr D. Fyfe

  

	21.3	For the purposes of this clause 21, “Business Day” shall mean any day other than a Saturday, Sunday or Bank or Public Holiday in the United Kingdom or Germany.

  

	22.	GOVERNING LAW AND JURISDICTION 

  
 The construction, validity and performance of this Agreement shall be governed by the laws of England. 
  

	23.	COUNTERPARTS 

  
 This Agreement may be entered into in any number of counterparts and by the parties to it on separate counterparts each of which when executed and delivered shall be an original but all these counterparts shall
together constitute one and the same instrument. 
  

 38 

 SCHEDULE 1 
  
 Claims under the Assigned Patent 
  
 The following claims in WO 0055927 (and the corresponding claims in all patents claiming priority therefrom including associated or national
regional patents and continuations thereof): 
  
 Claims 1 to 3, 6 to 43, 45, 48,
50, 54, 55 and 57 to 64 
 Claim 65 (subject to clause 4.1 proviso) 

 SCHEDULE 2 
  
 Claims relating to Relevant Materials and organic semiconductors generally licensed to Covion 
  

											
	 CDT
ref.

	  	Publication
number

	  	Priority
date

	  	 Title / brief description

	  	Claims

	  	 Status

	 004
	  	WO
92/03491	  	22 Aug
1991	  	Patterning of Semiconductive Polymers / Forming a polymer with distinct regions	  	1-24	  	G: US, HK, EP
						
	 070
	  	WO
00/03950	  	14 Jul
1999	  	Method for preparing nanoparticles, which may affect optical or electronic properties of a material	  	1-37	  	P: US, EP (GB, DE, FR, NL), JP, KR, CN, HK
						
	 084
	  	WO
01/62822	  	25 Feb
2000	  	Polymers, their preparation and uses / Polymer comprising a conjugated electron transporting backbone with pendant hole transporting substituents.	  	1-4, 8-13,
16, 18-20	  	Published
						
	 208
	  	WO
01/62869	  	25 Feb
2000	  	Luminescent Polymer — red emitting polymer repeat unit comprising a trimer of thiophene and quinoxaline.	  	1-23, 25-29,
35-39,41-43	  	Published
						
	 213
	  	WO
01/66618	  	10 Mar
2000	  	Copolymer — hole transporting polymers comprising trifluommethyl substituted trimylamine repeat units.	  	1-6, 9-
11,14, 15	  	Published
						
	 OS1
	  	DE
19935377	  	7 Jul
1999	  	Fluorescent material for LED’s comprising polyarylene vinylene with aryl substituents	  	1-2	  	P: DE

  
 P = pending in the listed territory

  
 G = granted in the listed territory 
  
 Published = published as a PCT applicstion 
  

 41 

 SCHEDULE 3 
  
 Claims to Relevant Materials and organic semiconductors generally non-exclusively licensed to Sumitomo and 

over which option to take a non-exclusive licence granted to Dow 
  

											
	CDT
ref.

	  	Publication
number

	  	Priority date

	  	 Title /brief description

	  	Claims

	  	Status

	003	  	WO
92/03490	  	24 Aug
1990	  	Semiconductive copolymers for use in luminescent devices /Tuning copolymers	  	1-48	  	G: EP, US,
CA, HK P: JP
						
	008	  	WO
94/29883	  	10 Jun
1993	  	Polymers for optical devices / PAV with solubilising and electron withdrawing groups	  	1-45	  	G: US P: EP
						
	012	  	US
5698048	  	9 Dec
1994	  	Photoresponsive materials / Organometallic complex	  	1-9	  	G: US, GB
						
	023	  	WO
96/20253	  	28 Dec
1994	  	Polymers for use in optical devices / Cross linking polymers	  	1-16, 21-33	  	G: EP P: US,
JP
						
	038	  	WO
98/32783	  	28 Jan
1997	  	Rheology modification of precursor solutions / Method for tailoring polymer viscosity	  	1-21	  	G: US, GB
						
	048	  	WO
99/20711	  	21 Oct
1997	  	Polymeric materials for electroluminescent devices / PPVs with blue-shifting substituents	  	1-16	  	P: EP, US, JP
						
	058	  	GB2328442	  	31 Mar
1998	  	Conjugated polymers for luminescent devices / Controlling cis / trans ratio of PAVs	  	1-21	  	P: GB, US
						
	072	  	WO
99/12989	  	5 Sep 1997	  	Compounds for electronic devices / Fused thiophenes	  	1-11	  	P: EP, JP, US
						
	074	  	GB
2340304	  	21 Aug
1998	  	Organic light emitters / controlling emission colour by blend composition	  	14-16, 18	  	P GB, US
						
	089	  	WO
00/53656	  	5 Mar
1999	  	Polymer preparation /Use of organic base	  	1-13, 15-18	  	P: US, EP, JP,
KR, CN, CA
						
	108	  	WO
01/07502	  	24 Jul
1999	  	Polymerisation method / Regioselective substitution	  	1-26, 28-38	  	Published
						
	200	  	WO
00/60612	  	6 Apr 1999	  	Method for doping a polymer / Forming a less than fully doped polymer	  	1-25	  	Published

  
 P = pending in the listed territory

  
 G = granted in the listed territory 
  
 Published = published as a PCT application 
  

 42 

 SCHEDULE 4 
  
 Other claims to Relevant Materials and organic semiconductors generally 
 non-exclusively licensed to Sumitomo 
  

											
	CDT
ref.

	  	Publication
number

	  	Priority
date

	  	 Title / brief description

	  	Claims

	  	Status

	033	  	WO
98/04610	  	29 July
1996	  	Conjugated copolymers for use in luminescent devices / Process for preparing PAVs	  	1-17	  	P: EP,
US, JP
						
	047	  	WO
98/13408	  	28 Sep
1997	  	High efficiency luminescent copolymers / PPV copolymers with certain substituents	  	1-23	  	G: HP P:
US, JP
						
	088	  	WO
01/49769	  	5 Jan
2000	  	Polymers, their preparation and uses / Certain heteroarylamino copolymers	  	1-27	  	Published
						
	175	  	WO
01/49768	  	5 Jan
2000	  	Luminescent polymer / Trimer repeat units	  	1-8, 10-14,
25-27	  	Published

  
 P = pending in the listed territory

  
 G = granted in the listed territory 
  
 Published = published as a PCT application 
  

 43 

 SCHEDULE 5 
  
 Claims to Relevant Materials and organic semiconductors generally owned/jointly owned by SEC 
  

											
	CDT
ref.

	  	Publication
number

	  	Priority
date

	  	 Title /brief description

	  	Claims

	  	Status

	103	  	WO
01/16251	  	31
August
1999	  	A Formulation for Depositing a Light-Emitting Polymer Layer / Alkylbenzenes and terpenes as inkjet solvents	  	1-13,
16-22	  	Published
						
	288	  	WO
00/59267	  	29
March
1999	  	Composition, method for preparing film and functional element and method for preparing the same / Alkylbenzenes as inkjet solvents	  	1-14,
16-23	  	P: US, EP,
JP, CN,
KR, TW

  
 P = pending in the listed territory

  
 G = granted in the listed territory 
  
 Published = published as a PCT application 
  

 44 

 SCHEDULE 6 
  
 Claims making reference to Relevant Materials licensed to Covion 
  

											
	CDT
ref.

	  	Publication
number

	  	Priority
date

	  	 Title / brief description

	  	 Claims

	  	 Status

	003	  	WO
92/03490	  	24 Aug
1990	  	Semiconductive copolymers for use in luminescent devices / Tuning copolymers	  	 49 - 50 (subject to
 clause 3.3
 proviso), 51
	  	 G: EP, US,
 CA, HK,
 P: JP

						
	004	  	WO
92/03491	  	22 Aug
1991	  	Patterning of Semiconductive Polymers /Forming a polymer with distinct regions	  	25-26 (subject to clause 3.3 proviso)	  	G: US, HK, EP
						
	008	  	WO
94/29883	  	10 Jun
1993	  	Polymers for optical devices / PAV with solubilising and electron withdrawing groups	  	46-62 (subject to clause 3.3 proviso), 63-66	  	G: US P: EP
						
	012	  	US
5698048	  	9 Dec
1994	  	Photoresponsive materials / Organometallic complex	  	10-14 (subject to clause 3.3 proviso)	  	G: US, GB
						
	023	  	WO
96/20253	  	28 Dec
1994	  	Polymers for use in optical devices / Cross linking polymers	  	19-20 (subject to clause 3.3 proviso), 17-18	  	G: EP P: US, JP
						
	033	  	WO
98/04610	  	29 July
1996	  	Conjugated copolymers for use in luminescent devices / Process for preparing PAVs	  	18-20 sod 22-23 (subject to clause 3.3 proviso), 21	  	P: EP, US, JP
						
	047	  	WO
98/13408	  	28 Sep
1997	  	High efficiency luminescent copolymers / PPV copolymers with certain substituents	  	24-25 (subject to clause 3.3 proviso)	  	G: EP P: US, JP
						
	048	  	WO
99/20711	  	21 Oct
1997	  	Polymeric materials for electroluminescent devices / PPVs with blue-shifting substituents	  	17-25 (subject to clause 3.3 proviso), 26-29	  	P: EP, US, JP
						
	058	  	GB2328442	  	31 Mar
1998	  	Conjugated polymers for luminescent devices / Controlling cis / trans ratio of PAVs	  	22-23 (subject to clause 3.3 proviso), 24	  	P: GB, US

  

 45 

											
						
	072	  	WO
99/12989	  	5 Sep
1997	  	Compounds for electronic devices / Fused thiophenes	  	12-26 (subject to clause 3.3 proviso), 27 - 31	  	P: EP, JP, US
						
	084	  	WO
01/62822	  	25 Feb
2000	  	Polymers, their preparation and uses / Polymer comprising a conjugated electron transporting backbone with pendant hole transporting substituents.	  	22-24 (subject to clause 3.3 proviso), 21	  	Published
						
	088	  	WO
01/49769	  	5 Jan
2000	  	Polymers, their preparation and uses / Certain heteroarylamino copolymers	  	29-33 (subject to clause 3.3 proviso), 28, 34-38	  	Published
						
	089	  	WO
00/53656	  	5 Mar
1999	  	Polymer preparation / Use of organic base	  	19-20 (subject to clause 3.3 proviso)	  	P: US, EP, JP, KR, CN CA
						
	108	  	WO
01/07502	  	24 Jul
1999	  	Polymerisation method / Regioselective substitution	  	39-41 and 45 (subject to clause 3.3 proviso), 42-44	  	Published
						
	175	  	WO
01/49768	  	5 Jan
2000	  	Luminescent polymer / Trimer repeat units	  	15-21 (subject to clause 3.3 proviso), 23-24	  	Published
						
	200	  	WO
00/60612	  	6 Apr
1999	  	Method for doping a polymer / Forming a less than fully doped polymer	  	27-29 (subject to clause 3.3 proviso), 26	  	Published
						
	208	  	WO
01/62869	  	25 Feb
2000	  	Luminescent Polymer — red emitting polymer repeat unit comprising a timer of thiophene and quinoxaline.	  	32-34 (subject to clause 3.3 proviso), 30-31, 40	  	Published
						
	213	  	WO
01/66618	  	10
Mar
2000	  	Copolymer – hole transporting polymers comprising trifluoromethyl substituted triarylamine repeat units	  	12-13 (subject to clause 3.3 proviso)	  	Published
						
	OS1	  	DE
19935377	  	7 Jul
1999	  	Fluorescent material for LED’s comprising polyarylene vinylene with aryl substituents	  	4-7 (subject to clause 3.3 proviso), 3	  	P: DE

  
 P = pending in the listed territory

  
 G = granted in the listed territory 
  
 Published = published as a PCT application 
  

 46 

 SCHEDULE 7 
  
 Claims making reference to Relevant Materials owned/jointly by SEC 
  

											
	 CDT
ref.

	  	Publication
number

	  	Priority
date

	  	 Title / brief description

	  	 Claims

	  	 Status

	 288
	  	WO
00/59267	  	29
March
1999	  	Composition, method for preparing film and functional element and method for preparing the same / Alkylbenzenes as inkjet solvents	  	24-35 (subject to clause 5.3 proviso)	  	P: US, EP, JP, CN, KR, TW

  
 P = pending in the listed territory

  
 G = granted in the listed territory 
  
 Published = published as a PCT application 
  

 47 

 IN WITNESS whereof the parties have executed this Agreement on the date first above written. 
  

			
	 Signed for and on behalf of

	 CAMBRIDGE DISPLAY TECHNOLOGY LIMITED

	  
 (Signature)
	 	  
 /s/ David Fyfe

	 (Name)
	 	 David Fyfe

	  
 (Position)
	 	  
 CEO

	  
 (Date)
	 	  
 14 December
2001

  

			
	Signed for and on behalf of 
	 COVION ORGANIC SEMICONDUCTORS GMBH

	  
 (Signature)
	 	  
 /s/ Hermann Schenk

	 (Name)
	 	 Hermann Schenk

	  
 (Position)
	 	  
 Geschäftsführer

	  
 (Date)
	 	  
 14/12/01

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00075-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00075-of-00352.parquet"}]]